Establishment and investigation of tendon-derived cell lines immortalized by the human telomerase reverse transcriptase gene. by Poppe, Sophia
 Establishment and investigation of tendon-
derived cell lines immortalized by the human 
telomerase reverse transcriptase gene.
Aus der Chirurgischen Klinik und Poliklinik – Innenstadt,
der Ludwig-Maximilians-Universität München
Direktor: Prof. Dr. med. Wolf Mutschler
 Dissertation 
zum Erwerb des Doktorgrades der Medizin
an der Medizinischen Fakultät der
Ludwig-Maximilians-Universität zu München
vorgelegt von: Sophia Amina Poppe 
aus München, im Jahr 2010
Mit Genehmigung der Medizinischen Fakultät
der Universität München
Berichterstatter: Prof. Dr. med. Matthias Schieker
Mitberichterstatter: Prof. Dr. Günther Eißner
   Prof. Dr. Peter Müller
Mitbetreuung durch die 
promovierten Mitarbeiter:  Dr. rer. nat. Denitsa Docheva 
   
Dekan:  Prof. Dr. med. Dr. h.c. M. Reiser 
   FACR, FRCR  
Tag der mündlichen  
Prüfung:  08. Juli 2010
1.........................................................................................................................1. INTRODUCTION 4
.........................................................................................................1.1. General background 4
..............................................1.1.1. Anatomical and molecular structure of tendons 4
................................................................................................1.1.1.1. Tendinous tissue 4
............................................................1.1.1.2. Osteotendinous junction - enthesis 5
...................................................................................1.1.1.3. Myotendinous junction 7
.......................................................................................1.1.2. Development of tendons 8
................................................................................1.1.3. Principles of tendon healing 10
................................................................................................................1.2. Clinical aspects 12
........................................................................................................1.2.1. Tendon injuries 12
..........................................................................................................1.2.2. Tendon repair 16
...........................................................................................................1.3. Tenocytes in vitro 18
.............................................................................................1.3.1. Culture of tenocytes 18
.............................................................................1.3.2. Immortalization of tenocytes 19
..........................1.3.2.1. Immortalization by using SV40 large T antigen gene 19
................................................................1.3.2.2. Immortalization by using hTERT 19
............................................1.4. Significance of performing research with tenocytes 23
............................................................................................2. DEFINITION OF THE PROJECT 24
................................................................................................2.1. Main aim of the project 24
............................................................................................2.2. Milestones of the project 24
...............................................................................................3. MATERIALS AND METHODS 25
..................................................3.1. Establishment of a primary culture of tenocytes 25
.............................................................................3.1.1. Isolation of human tenocytes 25
..............................................................................................3.1.1.1. Tendon samples 25
..................................................................................3.1.1.2. Isolation of tenocytes 25
........................................................................3.1.2. Cultivation of human tenocytes 26
.......................................................................................................3.1.2.1. Cell culture 26
...............................................................................3.1.2.2. High density cell culture 27
.................................................................................................3.1.2.3. Cell passaging 27
.....................3.1.2.4. Determination and plating of a defined number of cells 27
2............................................................................3.1.2.5. Cryoconservation of cells 29
....................................................................................................3.1.2.6. Cell thawing 29
..............................................3.1.3. Calculation of cumulative population doubling 29
.......................................................................3.2. Cell transduction by hTERT lentivirus 30
...............................3.2.1. Lentivirus production and transduction of human cells 30
...................................................................................................3.2.2. Single cell cloning 32
.....................................................................................................3.3. Methods for analysis 34
.....................................................................................................................3.3.1. RT-PCR 34
..................................................................................................3.3.1.1. RNA isolation 34
..............................................................................................3.3.1.2. cDNA Synthesis 34
..........................................................................3.3.1.3. Polymerase chain reaction 34
........................................................................3.3.1.4. Agarose gel electrophoresis 36
.........................................................................................3.3.2. Immunocytochemistry 37
...............................................................................................3.3.2.1. Fixation of cells 37
.....................................................................................3.3.2.2. Immunofluorescence 37
3.3.3. Senescence-associated β ............................................–galactosidase assay 38
.......................................................................................3.3.4. Telomerase activity test 39
.......................................................................................................3.3.5. Soft agar assay 40
......................................................................................................................3.4. Microscopy 41
..........................................................................................................3.5. Statistical analysis 41
....................................................................................................................................4. RESULTS 42
......................................................................................4.1. Primary culture of tenocytes 42
........................................................................................................4.1.1. Tendon donors 42
....................................................4.1.2. Tenocyte outgrowth and tendon digestion 42
..........................................................................................................4.2. hTERT-expression 43
........................................................................................................4.2.1. hTERT RT-PCR 43
............................................................................4.2.2. hTERT immunocytochemistry 44
..........................................................................4.2.3. Analysis of telomerase activity 44
...........................................................................................................4.3. Single cell cloning 45
...............................................................................................................4.4. Growth kinetics 46
3...................................4.5. Cell morphology of primary and hTERT-transduced cells 48
.......................................................................................................4.6. Senescence analysis 50
...............................................................................4.7. Tendon-related gene expression 52
.................................................................................4.8. Long-term high density culture 54
.................................................................................4.9. In vitro tumourigenicity analysis 54
.............................................................................................................................5. DISCUSSION 56
........................................................................................................................6. CONCLUSIONS 65
...........................................................................................................................7. PERSPECTIVE 66
................................................................................................................................8. SUMMARY 67
...........................................................................................................9. ZUSAMMENFASSUNG 68
...........................................................................................................................10. LITERATURE 69
..............................................................................................................................11. APPENDIX 74
41. INTRODUCTION
1.1. General background
1.1.1. Anatomical and molecular structure of tendons
1.1.1.1. Tendinous tissue
Tendon is the essential connection between muscle and bone, whereas ligaments 
form the interconnection between bone and bone. Nevertheless both tissues are 
similarly structured and belong to the group of dense connective tissue and more 
precisely to the group of tendinous tissue. In research these tissues receive little 
attention. As opposed to cartilage or bone, very little is known about the 
microscopic and molecular structure of tendons and ligaments.
In the following, a detailed description of the anatomical structure of tendons with 
reference to different review articles is given. Tendons and ligaments do not have a 
consistent macroscopic appearance. Depending on the region of the body they can 
be flat, round, short or as drawn-out as the Achilles tendon stretching from the calf 
muscles to the heel bone. Some particularly flattened tendons for example in the 
ventral abdominal region are called aponeurosis (anterior abdominal aponeuroses). 
Other tendons need a synovial sheath (e.g. around the tendons of the extensor 
muscles at the hand) that has a protective function and reduces friction to ensure 
their functionality. Every tendon shows a structural hierarchy. From the outside 
inwards these are: tertiary bundles, fascicles (secondary bundles), fibrils, subfascicle 
(primary bundle), microfibrils (collagen fibre) and collagen fibril (tropocollagen). The 
epitenon surrounds the whole tendon, while the endotenon runs between the 
fascicles and tertiary bundles and contains blood vessels (see Figure 1). Yet under 
physiological conditions a fully developed tendon is a poorly vascularised tissue 
(Schieker et al. 2004). 
In every tendon the force that is regularly applied to it determines the main 
orientation of the fibres. When the tendon is in a resting state the fibrils lie in a wavy 
conformation, defined as crimp, while when force is applied, fibrils straighten out and 
the tendon becomes stiffer. Thus under tensile stress and strain, tendons are 
resilient but flexible enough to adapt to the mechanical demands of their 
environment.
5Figure 1. Structural hierarchy of tendons (Riley G, Expert Reviews in Molecular Medicine, Cambridge 
University Press 2005).
On a molecular basis tendinous tissue can be divided into a cellular part, consisting 
mainly of mesenchyme-derived tenocytes and tenoblasts, and of an extracellular 
part (extra-cellular matrix, ECM), which is produced and maintained by the cells. In a 
mature tendon less than 5 % of the whole volume consist of cells. Cells that do 
occur are mainly tenocytes but also chondrocytes, synovial cells and vascular cells, 
which exhibit low mitotic activities.
Besides the high percentage of water (65-75 %), the dry mass of a tendon contains 
mostly collagen I, which is found in all connective tissues in different quantities. 
Other components are elastin, collagen type III, IV, V and VI as well as proteoglycans 
(decorin, aggrecan etc.) and structural glycoproteins. The latter two form the so-
called ground substance that stabilizes the tenocytes within the collagen fibres. Very 
importantly some of the constituents serve as markers for a tenogenic profile, as 
will be further elaborated in chapter 4.7 (O‘Brien et al. 1997, Tozer and Duprez 
2005, Sharma et al. 2006, Hoffmann et al. 2006).
1.1.1.2. Osteotendinous junction - enthesis
Other than the above mentioned main structure, there are areas where the tendon 
meets the demands of a different kind of strain. This means tendons do not only 
directly transmit the force from the muscle to the bone but they also have to sustain 
increased pressure as a hypomochlion e.g. the Patellar tendon where the tendon 
transfers the force from the thigh to the lower leg via the patella. This can only be 
achieved by a change of the composition of the ECM. One very important part of 
6the tendon where this change of ECM is essential is the osteodendinous junction 
which is also called ‛enthesis’. This is the area where the tendon anchors to the 
bone. Generally speaking the change of ECM is a change of connective tissue. As 
cartilage is the tissue that is primarily specialized to sustain pressure and cyclic 
loading, the enthesis contains fibrous cartilage in some regions. Although this 
attachment site is schematically divided into four zones: tendon, fibro-cartilage, 
calcified fibrocartilage and bone, it is merely a smooth transition (Benjamin et al. 
1986). Knese and Biermann 1958 were among the first to describe the enthesis in 
greater detail. Based on their definition Benjamin and Ralphs 1995 later classified 
the entheses as fibrous and fibro-cartilaginous. The fibrous enthesis is additionally 
divided into bony and periosteal segments, depending on the attachment site of 
either bone or periost. Opposedly, the fibrocartilaginous enthesis consists of the 
four zones already described above.
Obviously the attachment site is a zone of increased stress. Not only do two 
different connective tissues, tendon and skeletal tissue, have to interact here, but 
also does the enthesis have to balance the deviant elastic moduli of both (Knese and 
Biermann 1958). Tendons and ligaments are able to decrease their diameter in 
response to distension to a certain extent. At attachment sites this deformation 
would lead to high shear stress, which is not tolerable as it would compromise the 
connection between bone and tendon. Fibrocartilage does not give way to 
distension and therefore entheses contain fibrocartilage in order to withstand 
mechanical strain (Milz et al. 2005). 
As aforementioned, the ECM in the enthesis is altered due to functional adaptation. 
On a molecular basis this denotes not only a change in the molecular composition of 
the ECM but also a change of the cells themselves. While molecules typically 
present in hyaline cartilage and dense connective tissue increase, the ECM 
components of tendon decrease. This correlates with a rise of collagen II, aggrecan, 
link-protein and chondroitin-6-sulfat for hyaline cartilage and collagen I, collagen III, 
dermatan sulfate, keratan sulfate and versican for dense connective tissue (Milz et 
al. 2005). Entheses are easily integrated in a clinical context when being aware of 
the molecular composition. Because of the fact that entheses are poorly 
vascularised their healing potential is marginal. Yet there are other reasons for the 
entheses to be clinically relevant and therefore represent an interesting object for 
investigation. Entheses appear to be objectives in the clinical manifestation of 
rheumatoid arthritis. They contain comparatively high amounts of aggrecan, link 
7protein and collagen II. These three molecules have been detected to be 
autoantigens during the autoimmune response in patients with rheumatoid arthritis 
(Glant et al. 1998, Guerassimov et al. 1998, Myers et al. 2001).
1.1.1.3. Myotendinous junction
Tendons, unlike ligaments, form a connection between bone on the one and muscle 
on the other side. They are the middle piece of the force transmitting entity, 
consisting of myotendinous junction (connecting muscle and tendon), tendon and 
enthesis. Therefore the myotendinous junction performs complex tasks which is 
reflected in its equally complex structure. Muscle and tendon virtually interdigitate. 
The fibres of the muscle are surrounded by plasma and basement membranes while 
they form a network with collagen fibres, fibroblasts and their processes. 
Accordingly there is no direct contact between collagen fibril and muscle fibres. 
Furthermore, the terminal parts of the fibres have electron dense zones of 
thickened plasma membrane to which the filaments of the I-bands (surrounding the 
Z-line of the sarcomere) are attached (Mair et al. 1972). From a physical point of 
view, the interdigitation amplifies the surface area of the ‛contact zone’ and thus 
reduces the shear stress that is transmitted through contractile forces. More 
precisely, the degree of surface amplification is proportional to the amount of stress 
reduction (Trotter et al. 1985). 
As seen in the entheses, the ECM composition changes in response to a different 
mechanical need. The same phenomenon occurs in the myotendinous junctions. 
Especially the expression of focal adhesion kinase, paxillin, integrin-linked kinase, 
mitogen-activated protein kinase and talin is increased. The increase in paxillin and 
talin was as well used and seen when tendon-skeletal muscle constructs engineered 
in vitro were evaluated (Larkin et al. 2006). In embryonic development the 
formation of a myotendinous junction passes through five different stages: a. close 
association of the cell with tendon collagen fibres, b. basement membrane 
formation, c. sarcolemmal folding, d. appearance of subsarcolemmal densities, and e. 
myofibril association with subsarcolemmal densities. Afterwards, the junction only 
gains quantity during its embryonic development. Furthermore the number of cells 
near the junction decreases over time while the associations between basement 
membrane and collagen fibres increase (Tidball and Lin 1989).
In general, injuries at this site represent a major clinical problem. It is essential to 
diagnose the patients with this kind of injury correctly, especially because 
8musculotendinous junction injuries are rather common (Noonan et al. 1992). These 
patients face unspecific symptoms such as pain, oedema and ecchymosis. Compared 
to other injuries in this area, musculotendinous injuries need different treatment 
regimes. Since suturing muscular tissue is often associated with complications such 
as re-rupture, common surgical interventions are not recommended and other 
conservative treatments such as rehabilitation and a home exercise program are 
preferred and present with better results (Schamblin and Safran 2007).
1.1.2. Development of tendons
Tendon development is a precondition to enthesis or myotendinous junction 
formation, while the (embryonic) development is probably the least known aspect 
of them. As the healing or intrinsic repair of injured tissues often resembles the 
development, in that some processes on a cellular and molecular basis are being 
repeated, the knowledge of the development is crucial for the understanding of 
tendon repair. Generally, a distinction is made between the development of limb 
tendons (proximal and distal) and axial and ventrolateral wall tendons. The different 
kinds of tendons do not only have different localizations but they also differ in their 
development especially relating to their behaviour in absence or presence of 
muscles (Schweitzer et al. 2001). D‘Souza et al. 1999 examined two genes in 
chicken, follistatin and EphA4, which are both expressed during tendon 
development. The removal of an interdigital apical ectodermal ridge led on the one 
hand to formation of cartilage and on the other hand to induction of EphA4 and 
follistatin which are both associated with tendon formation. As a result of their 
study, they concluded that cartilage and tendon development are coordinated. 
To date, only Scleraxis (Scx), a basic helix-loop-helix transcription factor, is known 
as a single marker for tendons and ligaments. It is expressed in all of the developing 
tendons and therefore represents an adequate marker for tracking tendon 
development in general. The embryogenesis of the musculoskeletal system is well 
understood: The axial skeleton evolves from the sclerotome, the skeletal muscle 
from the myotome and the dorsal dermis from the dermotome. By analyzing the 
expression of Scleraxis it was possible to identify a fourth somitic compartment 
named the ‛syndetome’ from which tendons and ligaments evolve (Brent et al. 
2003). More recent studies of Brent et al. partially identified the molecular 
interactions between the four somitic compartments. Myotomal Fibroblast growth 
factor (FGF) acts on the somitic tendon progenitors through the activation of the 
mitogen-activated protein kinase (MAPK) pathway and subsequently of the 
9transcription factor Pea3 (ETS family transcription factor) which then stimulates 
Scleraxis expression in tendon progenitors of the syndetome. Figure 2 illustrates the 
molecular interactions among the four somitic compartments, dermomyotome, 
myotome, syndetome and sclerotome. The myotome signals positively to the 
syndetome, while the sklerotome actively represses the syndetome by Sox5/Sox6-
dependent transcription. Moreover, the authors demonstrated in their study that 
when the development of cartilage is blocked by a Sox5/Sox6 double mutation or 
knockout, ectopic Scleraxis expression is induced in the sclerotome. This leads to the 
assumption that tendon development is repressed under normal conditions by 
chondrogenic development, indicating that chondrogenic development influences 
tendon development and vice versa (Brent et al. 2004 and 2005).  
At a later stage of the development, collagen fibrillogenesis plays a substantial role. 
This does not only hold true for the embryological development, but also for all 
healing processes in the adult tendon. Tenocytes are responsible for the assembly of 
the collagen fibre network. In the case of tropocollagen, which is the basic protein 
unit of collagen fibres, this process takes place intracellularly. For a long time it was 
assumed that in vivo tropocollagen monomeres self-assemble into collagen fibrils as 
seen in vitro. But this opinion was revised when the collagen fibril segment as a basic 
component of the collagen fibril was discovered. These segments are assembled to 
collagen fibrils in deep extracellular recesses located on the cell surface of tenocytes. 
When the collagen fibril increases in length, the plasma membrane walls of the 
recesses are retracting. In order to form collagen macroaggregates and to allow a 
growth in diameter, more than one tenocyte takes part in the assembly (Ingraham et 
al. 2003). Subsequently the association of the glycosaminoglycan decorin stabilizes 
the fibrils (Zhang et al. 2006). Ingraham et al. 2003 proposed that tendon 
fibrillogenesis during repair is related to the fibrillogenesis of embryonic tendon 
development by repeating the process that was described above in mature injured 
tendon.
10
Figure 2. Proposed model of the development of somitic tendon progenitors. (Hoffmann and Gross, 
Regenerative Medicine 2006)
1.1.3. Principles of tendon healing
In general, tendon is a tissue with low regenerative capacity. The process of 
tendinous tissue repair is divided in three merging phases, which are illustrated in 
Figure 3. Phase one, the inflammatory phase, directly follows the injury. It is 
characterized by the migration of inflammatory cells such as leukocytes, neutrophils 
and macrophages together with fibroblasts from the epitenon attracted by pro-
inflammatory factors from mast cells. These cells remove cellular debris, collagen 
fragments and help to dispose of the haematoma that is formed because of the 
damage of the surrounding blood vessels. The increased vascular permeability 
permits a release of vasoactive and chemotactic factors. In addition, angiogenesis is 
initiated by upregulation of platelet derived growth factor (PDGF), epidermal 
growth factor (EGF) and TGF-β1 and tenocytes are stimulated to proliferate. A 
higher deposit of DNA, fibronectin, glycosaminoglycan, water and collagen type III 
stabilizes the ECM at the repair site. 
The next phase - called the fibroblastic/collagen synthesis phase - is predominantly 
marked by the further proliferation of epitenon and endotenon fibroblasts and the 
synthesis of collagen type III (Maffulli et al. 2000).  
At the beginning of the third phase - remodelling/maturation phase - fibroblasts 
decrease in size and reduce the production of ECM. Collagen fibres commence to 
align in the direction of stress and more collagen type I is produced. It takes up to 
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one year for the healing fibrous tissue to change into a permanent scar-like tissue. 
The tissue that is formed after repair leaves a functional gap to healthy tendinous 
tissue (reviewed by Fenwick et al. 2002; Ingraham et al. 2003; Lin et al. 2004; 
Sharma and Maffuli 2006).
Figure 3. The different phases of tendon healing. (1) Inflammatory phase, (2) Fibroblastic/collagen 
synthesis phase, (3) Remodelling/maturation phase 
(adapted from Gomez M, 1995)
Tendon can either heal intrinsically or extrinsically. During intrinsic healing the 
fibroblasts within the tendon proliferate, cells from the epitenon layer of fibroblasts 
differentiate into cells that resemble phagocytes and endotenon originated cells 
synthesize collagen. For intrinsic healing intratendinous blood supply is sufficient and 
therefore the risk of adhesion formation is diminished. By contrast the extrinsic 
healing depends on an extratendinous blood supply and the infiltration of 
inflammatory cells and fibroblasts from the surrounding sheath and synovium. When 
cells from outside the tendon migrate into the repair site and vessel ingrowth is 
induced, adhesions form and impair the normal function of the tendon gliding. Thus, 
extrinsic healing is considered to be inferior to intrinsic healing. Taking this into 
account, surgery after intrasynovial tendon injury needs to be deliberate as it 
disrupts the synovial sheath, enhances extrinsic healing and therefore adhesion 
formation. Most likely tendon healing occurs as a combination of intrinsic and 
extrinsic healing and is dependent on the location, the severity of the trauma, the 
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blood supply and some minor factors. Still a better understanding of this process 
would help to improve surgical methods or to advance non-invasive therapies 
(Manske et al. 1984; Sharma and Maffuli 2006; Lin et al. 2004). Wiig et al. 1997 
attempted to accelerate tendon healing by reducing adhesions with hyaluronan 
injections between tendon and surrounding sheaths. Unfortunately this method had 
no effect on the healing process. To date there are few methods to repair tendon 
injuries, some using autografts, allografts or synthetic prostheses with the most 
widely used approach being tendon sutures. Newest approaches even include gene 
therapy, but they are still experimental. So far none of the therapeutic options has 
provided a successful long-term solution and at best the restored tendons are about 
60 % functional (Rees et al. 2006).
1.2. Clinical aspects
1.2.1. Tendon injuries
Tendon injuries can result from diverse causes and lead to various symptoms. They 
may be classified as acute or chronic and be either direct or indirect. Intrinsic and 
extrinsic factors such as growth factors, hypoxia, ischaemic damage, inflammatory 
mediators, trauma and treatment also exert their influence. Acute and direct injuries 
with an immediate impact are found in contusions, injuries from accidents, sports 
injuries or lacerations by sharp objects. By contrast, indirect tendon injuries are most 
likely the result of tensile overload and repetitive microtrauma due to overuse (for 
an overview see Figure 5). In general, the connective sites, osteotendinous and 
myotendinous junctions, are more susceptible to ruptures and other forms of injury 
than healthy tendons, because they cannot withstand as much tensile load. Common 
examples are the so-called tennis elbow (tendinosis of extensor carpi radialis brevis 
and longus tendons usually within 1-2cm of their attachment to the lateral 
epicondyle of the humerus), the golfers elbow (tendinosis of the flexor carpi radialis 
tendon within 1-2 cm of its attachment to the medial epicondyle of the humerus) 
or the baseball-pitchers shoulder (insertion sites of tendons of rotator cuff 
muscles). Therefore, ruptures in the middle of a healthy tendon occur much less 
frequently (reviewed by Lin et al. 2004; Sharma and Maffuli 2006).
In the US, Patients sustain more than 32 million traumatic and repetitive motion 
injuries to tendons and ligaments every year. One of the most common is the rotator 
cuff injury of the shoulder. It is estimated that more than half of the population over 
the age of 80 years experience rotator cuff injuries (Schoen DC 2005, Tempelhof et 
al. 1999, Loehr et al. 2007). Sometimes tendons rupture spontaneously. In these 
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cases the ultrastructure is presumably altered. Kannus and Jozsa 1991 evaluated 
specimens of spontaneously ruptured tendons of 981 patients. Not one of the 
evaluated ruptured tendons had a healthy structure (Figure 4). 97 % of the 
pathological changes were degenerative, including hypoxic degenerative 
tendinopathy, mucoid degeneration, tendolipomatosis and calcifying tendinopathy, 
either alone or in combination. In the remaining 3 % the pathological change was one 
of the following: intratendinous foreign body, rheumatoid tendinitis, a xanthoma, a 
tumour or a tumour-like lesion.
Figure 4. Histopathology of tendinopathy. (a) Normal flexor tendon histology, showing organised 
parallel fibre bundles and long thin tenocytes dispersed throughout the matrix. (b) Ruptured 
supraspinatus tendon, showing hyaline appearance, loss of matrix organisation and rounded, shrunken 
nuclei. (c) Glycosaminoglycan (GAG, blue) accumulation in supraspinatus tendon, GAG is surrounding 
rounded cells in the matrix. (d) ‘Angiofibroblastic’ change in painful Achilles tendinopathy, showing an 
increase in cell number and blood vessels. Staining: a,b and d stained with H&E, c stained with Alcian 
Blue and H&E (Riley G, Expert Reviews in Molecular Medicine, Cambridge University Press 2005).
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Figure 5. Interdependence of tendon pathology factors. Different intrinsic and extrinsic factors as 
well as certain diseases and advanced age lead to decreased tendon strength.
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Tendons as a connective tissue have the ability to adapt, remodel and repair within 
certain limits. In order to do so, ECM must be degraded and reestablished. 
Degenerative pathological changes may be the result of an imbalance in factors that 
are involved in this degradation and assembling process. These ‛factors’ are 
considered to be serine proteinases and particularly metalloproteinases such as 
MMP (matrix metalloproteinases), ADAM (A distegrin and metalloproteinases) and 
ADAMTS (A distegrin and metalloproteinases with trombospondin motifs). It is 
assumed that metalloproteinases are able to degrade major components of the 
tendon ECM and that their opponents, the tissue inhibitors of metalloproteinases 
(TIMP 1-4 in human), balance their activity. Nevertheless, TIMP are not the only 
antagonists of MMP as they also play a key role in normal tendon physiology e.g. in 
cell proliferation and apoptosis (Clegg et al. 2007). Another modulator that seems 
to be playing a decisive role in tendon healing is nitric oxide (NO). This free radical is 
synthesized by NO synthase from L-arginine. A study from Murrell et al. 1997 
investigated that NO synthase activity is induced during rat Achilles tendon healing. 
NO synthase activity increases five-fold until day 7 after tenotomy of rat Achilles 
tendons and returns to almost normal level on day 14. Inhibition of the NO synthase 
led to a significant reduction in cross-sectional area and failure load, indicating an 
inhibition of tendon healing when no or a reduced amount of NO is present.
Interestingly, fluoroquinolone antibiotics can influence the expression of MMPs and 
hence promote tendon pain and rupture (Corps et al. 2005). For example, in 
Australia until 2002, 112 patients suffered from tendon disorders after 
fluoroquinolone therapy (mainly Ciprofloxacin). 30 cases involved tendon rupture 
(Australian Adverse Drug Reactions Bulletin 21:15, Dec 2002). Pasternak et al. 
2006 showed that doxycycline (a tetracycline) also inhibits MMPs. Transacted 
tendons from rats treated with doxycycline showed significantly decreased force at 
failure and energy uptake concluding that tendon healing can be affected by 
doxycycline at clinically relevant serum concentrations.
However, the question which initial stimulus for the degradation process leads to 
tendon pain and rupture has yet to be answered. Arnoczky et al. 2007 discussed 
another aspect of the mechanobiological aetiopathogenesis of tendinopathy, 
whether it has its origin in the over-stimulation or the under-stimulation of tendon 
cells. Although they favour the hypothesis of under-stimulation as main source of 
tendinopathy, the topic remains object of further investigations.
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1.2.2. Tendon repair
Tendon injuries can severely impair a patient‘s quality of life. Moreover, the mean 
age of our population will increase and thus problems with tendon degeneration and 
injury will increase as well. For these reasons effective therapies of tendon lesions 
must be found.
First of all, tendon repair should take place as early as possible after the injury. 
Within 12 h of injury it is called primary repair, within 14 days delayed primary, 
secondary would be between 2 and 4 weeks and late secondary after this period 
(Wright P, 1999). Depending on the severity of the injury, the demands of the 
patients and the feasibility, an appropriate therapy is chosen. Currently the most 
common therapy remains surgery. However there are vast varieties of different 
suturing techniques (Amlang and Zwipp, 2006). In general, the advantages or 
disadvantages of a technique are hard to judge, but what is most important is the 
number of strands crossing the repair site since it was proven that the repair 
strength is directly proportional to this (Lin et al. 2004). There is no consistent 
agreement when and to which extent the repaired tendon should be permitted to 
move after the intervention. A complete immobilization leads to reduced mechanical 
performance, impaired function and promotes the generation of adhesions. Opposed 
to this, remobilization can cause the formation of tears or in the worst case can 
cause re-rupture while at the same time antagonizing the bad effects of 
immobilization (Hoffmann et al. 2006; Lin et al. 2004). Taken together, stating a 
guideline for the optimal post-surgical treatment regimen is not (yet) possible. 
Furthermore, there are cases where the tendon suffers from a critical size defect. 
Under certain circumstances (for instance in anterior cruciate ligament ruptures) the 
use of an autograft presents a possible solution although the restoration of tendon-
bone interfaces could prove to be complicated. Recently, there have been numerous 
studies concerning tendon replacement and tissue engineering of tendon (Ahmed et 
al. 2008; Annovazzi et al. 2009; Omae et al. 2008; Tsiridis et al. 2008).
Tissue engineering has the aim to augment the healing response by means of 
delivering cells seeded on a supporting scaffold to the repair site. Therefore three of 
the crucial targets of these studies are to select an adequate scaffold material, 
appropriate cell type as well as suitable environmental stimuli such as growth 
factors. Growth factors regulate a variety of cellular processes and are often 
indispensable for cell proliferation or differentiation of cells especially on scaffold 
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material. EGF and bFGF for example are factors promoting proliferation of fibroblasts 
during the tendon healing process (Table 1). Great demands are made on suitable 
scaffolds including biocompatibility, biomechanical stability, resilience and porosity. 
Regarding the cells, no unanimous consent has yet been found regarding the most 
suitable type for tissue engineering purposes. Undisputedly important, however, 
remain properties that are crucial for a successful outcome of any healing process 
such as a long life-span and high metabolic activity of differentiated cells. 
Particularly mesenchymal stem cells (MSCs) have been exhaustively tested. In most 
studies MSCs are used because of their relatively easy isolation and their potential 
to proliferate well in vitro. Also they do progress from an immature progenitor cell 
through various lineages e.g. the osteogenic, chondrogenic, adipogenic and 
especially tenogenic lineage into specific cells of the respective path (Pittenger et al. 
1999, Kuo et al. 2008). 
Table 1. Growth factors involved in tendon healing
Factor Biological effects
bFGF Proliferation of fibroblasts                                    
Enhanced collagen deposition                             
Increase in wound tensile strength
EGF Proliferation of fibroblasts
Enhanced collagen deposition                             
Increase in wound tensile strength
EGR-1 Upregulation of TGF-β, PDGF, HGF and VEGF 
Enhanced angiogenesis                                       
Enhanced collagen deposition
HGF/SF Enhanced angiogenesis                                       
Enhanced collagen deposition
PDGF-B Influx of mononuclear cells and fibroblasts      
Enhanced collagen deposition                            
Enhanced Angiogenesis                                        
Increase in wound tensile strength        
TGF-β Migration of mononuclear cells and fibroblasts     
Enhanced collagen deposition                             
Increase in wound tensile strength
VEGF Enhanced angiogenesis                                      
Enhanced granulation tissue deposition
In the field of tendon tissue engineering various combinations of matrices, cells and 
stimulating factors were tested. Different scaffold materials like polyglycolic acids, 
gels based on collagen type I or cross-linked collagen fibres served as matrix for 
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different types of cells ranging from tenocytes to MSCs. Butler et al. 2007 for 
example used a type I collagen sponge seeded with MSCs to repair defects in the 
patellar tendon in a rabbit model in vivo. Furthermore the constructs were 
mechanically stimulated prior to implantation into the defect site. This implant 
successfully enhanced the repair of the injured tissue and the dynamic load capacity 
significantly compared to untreated controls. Some factors indispensable for a 
positive outcome of tendon tissue engineering have already been detected. 
Beyond a suitable scaffold material and metabolically active cells, for instance, 
mechanical stimulation of the constructs has been proven to be a crucial factor for a 
favourable clinical outcome reflected in high biomechanical stability (Cao et al. 
2006; Zeugolis et al. 2008).
1.3. Tenocytes in vitro
1.3.1. Culture of tenocytes
Concerning the cultivation of tenocytes, a critical point is the preservation of a 
differentiated cell state. Earlier in vivo studies of avian and rabbit tendon cells 
showed decreased levels of type I collagen and decorin transcripts, and a loss of 
differentiated function during prolonged monolayer culture (Bernard-Beaubois et al. 
1997, Schwarz et al. 1976). Another study performed with human tenocytes 
suggested that the differentiated state of the tenocytes can be preserved when 
they are grown in a three dimensional culture system after initial monolayer 
expansion. A combination of ultrastructural, biochemical and molecular tools showed 
that the phenotypic identity of the tenocytes was retained. Taken together, high-
density culture may be useful as a new method for autologous tenocyte 
transplantation (Schulze-Tanzil et al. 2004). However, this approach does not allow 
extensive, long-term molecular analysis of tenocyte metabolism and signalling due 
to the use of primary cells, which have a limited lifespan. Also the high number of 
experimental cells needed presents a problem due to their limited availability. 
Besides, it would be interesting to further investigate the potential of tendon-
derived progenitors to differentiate into other mesenchymal cell lineages such as 
osteocytes, chondrocytes and adipocytes, claiming that tenocytes or tendon-
derived fibroblasts have a mesenchymal stem-cell-like character, thus supporting 
the hypothesis that there might be a role for altered tendon-cell differentiation in 
the pathophysiology of tendon injuries (de Mos et al. 2007).
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1.3.2. Immortalization of tenocytes
1.3.2.1. Immortalization by using SV40 large T antigen gene
A recent publication using murine tenocytes has demonstrated that after 
immortalization with SV40 large T antigen gene, several cell clones (TT-E4, TT-G11 
and TT-D6) maintained tendon phenotype-related gene expression (such as Scx, Six 
1, EphA4, COMP and type I collagen transcripts) during one year of continuous 
cultivation (Figure 6). 
Figure 6. Tenogenic profile. RT-PCR analysis of expression of genes related to tendon phenotype 
(Salingcarnboriboon et al. 2003).
Furthermore, these clonal cell lines formed tendon-like tissues when they were 
implanted into defects made in murine patella tendon. Interestingly, these cells 
expressed genes related to osteogenic, chondrogenic and adipogenic lineages at low 
levels when examined by RT-PCR, postulating the existence of mesenchymal stem 
cells in tendon tissue (Salingcarnboriboon et al. 2003).
1.3.2.2. Immortalization by using hTERT
The human telomerase reverse transcriptase gene (hTERT) encodes the catalytic 
subunit of human telomerase (Figure 7). This enzyme is a ribonuclear protein 
complex which maintains the telomere length. A telomere is a repeating sequence of 
double-stranded DNA located at the ends of chromosomes. As cells divide and 
differentiate throughout the lifespan of an organism or cell line, the telomeres 
become progressively shortened and lose the ability to maintain their length. 
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Telomerase is an enzyme that lengthens telomeres by adding on repeating 
sequences of DNA. Telomerase binds to the ends of the telomere via an RNA 
template that is used for the attachment of a new strand of DNA. Telomerase adds 
several repeated DNA sequences. A second enzyme, DNA Polymerase, attaches the 
opposite or complementary strand of DNA completing the double stranded 
extension of the chromosome ends (Figure 8). High levels of telomerase activity are 
detected in immortalized cell lines such as embryonic stem cells and cancer cells, 
whereas little or no telomerase activity is present in most mature, differentiated cell 
types. In the absence of hTERT, telomeres shorten during cell division resulting in 
cellular senescence and growth arrest (Harley et al. 1990). 
Figure 7. Structure of the catalytic subunit of telomerase, TERT (Protein Data Bank)
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Figure 8. Telomeres and Telomerase. (Winslow T 2001, Stem Cell Information,  Appendix C)
Successful immortalization of human mesenchymal stem cells (hMSCs) by retroviral 
as well as lentiviral overexpression of hTERT was previously reported. The 
immortalized cells retain their original characteristics, maintain functional activities 
and have an extended lifespan (Figure 9) (Simonsen et al. 2002, Boecker et al. 
2008).
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Figure 9. Important characteristics of the human mesenchymal stem cell line 
(SCP-1) expressing hTERT after lentiviral gene transfer. (A–C) Cell morphology at population 
doubling level (PDL) 31, 121 and 224 of SCP-1. (D, E) Senescence-associated β-galactosidase 
assay. Untransduced hMSC show pronounced 
β-galactosidase activity at PDL 24. In contrast, hTERT-transduced hMSCs had no 
β-galactosidase activity even at higher passages. (F) Growth curve of untransduced hMSC, 
heterogeneous hTERT-hMSCs and single-cell picked hMSC clones (G) BrdU assay of heterogeneous 
hTERT-hMSCs and SCP-1 showed a persistently higher proliferation of SCP-1 at young and later 
passages (Boecker et al. 2008).
However, in one of the studies few lines adopted a cancer stem cell-like phenotype 
and led to tumour formation in vivo probably due to spontaneous genetic changes 
(Burns et al. 2005). Opposedly, all of the obtained clonal cell lines from Boecker et 
al. 2008 had preserved their three-lineage differentiation potential, did not form 
tumours, and had normal karyotypes. In cases where neoplastic transformation of 
immortalized cells was reported it was mostly dependent on the viral vector used. 
The most common vectors used for immortalization of cells are retroviral and 
lentiviral vectors (see also chapter 5 Immortalization of cells - Transduction of 
tenocytes with hTERT avoids senescence).
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1.4. Significance of performing research with tenocytes
From the tendon developmental and molecular biological point of view, a number of 
questions remain to be answered in this current situation where tendon related 
injuries are becoming more common and no entirely satisfying treatment regimen 
has been developed as yet. First, in order to find and conceptualize promising 
treatment strategies, the ontogeny of the tenocyte lineage has to be analyzed in 
more detail as today it is only beginning to be understood. Secondly, only recently 
have markers been found enabling scientists to discriminate between tenocytes and 
other mesenchymal cell types. Now due care has to be exercised using this 
knowledge in order to analyze healing processes and cell-based therapeutic 
approaches in closer detail. Thirdly, tendon cell research has been hampered by the 
lack of appropriate (especially human) cell lines allowing long-term molecular 
characterization of the tenocytes in vitro. This problem can be overcome by the 
establishment of immortalized tenocyte lines allowing studies on live cells over 
prolonged periods of time. Taken together, research on tendon tissue and the 
reparation of tendon defects has not tapped its full potential yet. Using approaches 
such as the ones described above, combining more sophisticated analytical methods 
with cell lines appropriate for analyses of long range, both the biological properties 
of tendons and factors positively influencing their repair can be understood better, 
helping researchers to come up with new and innovative treatment options for 
tendon defects that are so far difficult to tend to.
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2. DEFINITION OF THE PROJECT
2.1. Main aim of the project
The main aim of the project was to establish and characterize a human tenocyte cell 
line by overexpression of the human telomerase reverse transcriptase gene using 
lentiviral transduction. 
2.2. Milestones of the project 
•  A first goal was to culture and expand primary tenocytes originating from human 
tendon specimens.
• In a second step, primary tenocytes were to be infected with lentivirus expressing 
hTERT and hTERT over-expression and activity was to be determined.
• Thirdly, immunohistochemical analysis for the protein expression of hTERT was to 
be performed.
• Another crucial goal was to obtain and expand tenocyte clonal cell lines. 
•   Consecutively, the growth capacities of the hTERT-transduced tenocytes by 
quantifying population doubling times (growth curve) were to be determined.
•   RT-PCR analysis for tenocyte specific markers such as Scleraxis, tenomodulin, 
type I and III collagen, COMP etc. had to be performed.
• Senescence of the cells had to be analyzed by performing senescence associated 
β-galactosidase assay.
• Finally, to test tumourigenicity of the cell line by applying in vitro tumour soft agar 
assay was one of the major goals of the project.
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3. MATERIALS AND METHODS
3.1. Establishment of a primary culture of tenocytes
3.1.1. Isolation of human tenocytes
3.1.1.1. Tendon samples
Our laboratory is part of the Department for Surgery of the University Hospital in 
Munich. All our tendon samples were acquired during regularly scheduled operations 
in the hospital. The samples originate from several types of tendons (mostly of the 
foot) such as Flexor hallucis longus tendon and were taken from leftover material. 
Before the operation, informed consent from all patients was obtained. The ethical 
grant was accepted by the ethical commission of the medical faculty of the LMU 
Munich (ethical grant-nr. 166-08). 
3.1.1.2. Isolation of tenocytes
The tendon samples were prepared with two different methods as published by 
Schulze-Tanzil et al. 2004 and Salingcarnboriboon et al. 2003.
Method 1: Immediately after the surgery the tendon sample was collected from the 
operation theatre in a sterile Falcon tube. First, it was transferred to 100 mm culture 
dish containing phosphate-buffered saline solution (PBS). Blood, other tissue 
remains and the epitenon membrane sheets were removed using sterile forceps and 
a scalpel. Using sterile scissors, the tendon was cut into small pieces of 
approximately 0,3 cm². All pieces were placed in 60 mm culture dishes containing 2 
ml tenocyte growth media. The pieces were equally distributed in the dish. Dishes 
were placed in an incubator at 37° C and 5 % CO₂. The medium was changed every 
three to four days by carefully sucking off the old medium with a sterile glass 
pipette and replacing it.
Material: cell culture incubator (Ser. No. 39709355, Jouan, France), 100 mm culture 
dish (Falcon, USA), 60 mm culture dish (Falcon), Falcon tubes (Sarstedt, Germany), 
PBS - phosphate buffered saline (NaH₂PO4 H₂O; Na₂H₂PO4, 2H₂O; NaCl Fa. Merck, 
Germany), surgical instruments, tenocyte growth medium (see 3.1.2.1.) 
Method 2: All samples were acquired and prepared as described above. Instead of 
placing the tendon pieces in culture dishes they were put in a sterile 15 ml Falcon 
tube containing 5 ml of tenocyte growth medium + 1,5 mg/ml Collagenase II. The 
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tube was placed in an incubator at 37° C for 16-20 h depending on the size of the 
individual pieces. Subsequently, the digested sample was filtered through a sterile 
nylon mesh (70 μm) into a new sterile Falcon tube. Next, the filtrate was 
centrifuged at 1000 rpm for 5 min. The supernatant was discarded and the cell 
pellet was resolved in tenocyte growth medium. Finally, cells were counted and 
plated in culture flasks at about 30-40 % density. 
Material: 100 mm culture dish (Falcon), 60 mm culture dish (Falcon), Falcon tubes 
(Sarstedt), nylon mesh (70 μm; Falcon) PBS (Merck), tenocyte growth medium (see 
3.1.2.1.), Collagenase II (Worthington, USA)
3.1.2. Cultivation of human tenocytes
3.1.2.1. Cell culture
Tenocytes were cultivated in growth medium (see Table 2) in an incubator at 37° C 
and 5 % CO₂. Partricin was only used in the early culture period for about 2 weeks. 
As soon as the cells were proven to be negative for fungi, bacteria and mycoplasms 
Partricin was omitted.  
Fetal Bovine Serum (FBS) was heat-inactivated prior to being added. Hence, 500 ml 
of FBS was slowly thawed at 4° C and subsequently inactivated for 20 min in a 
water bath at 56° C. After the heat-inactivation the serum was aliquotted again 
and stored at -20° C until utilization. 
Table 2 – Growth medium of tenocytes
Supplements Concentration Volume for 500ml Company
DMEM/HAM‘S 84 % 420 ml Gibco, USA
Fetal Bovine Serum (FBS) 10 % 50 ml Sigma, Germany
MEM-AS 2 % 10 ml Biochrom, Germany
Ascorbic acid-phosphate 1 % 5 ml Sigma
Glutamine 1 % 5 ml Biochrom
Penicilline/Streptomycin 1 % 5 ml Gibco
Partricin 1 % 5 ml Biochrom
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3.1.2.2. High density cell culture
For high density cell culture 5000 tenocytes were seeded per cm2 (6-well plate) 
and cultivated in tenocyte growth medium in an incubator at 37° C and 5 % CO₂. 
Medium was changed every 3-4 days. Cells were not passaged for more than 90 
days. 
3.1.2.3. Cell passaging
When a confluency of approximately 90 % was reached cell passaging was carried 
out as the cells were detached, counted and replated in cell culture flasks. All 
quantities refer to T75 (75 cm²) culture flasks. For 60 mm (21 cm²) and 100 mm 
(56 cm²) dishes or T25 (25 cm²) the amounts of cells were adapted according to 
the dish area.
Protocol for passaging tenocytes 
1. Remove medium, wash cells with PBS
2. Detach cells with 2 ml of a trypsin/EDTA-Solution 
3. After 7 min in the incubator at 37° C and 5 % CO₂ control detachment of 
cells by microscope
4. When all cells are detached, add 3 ml of tenocyte growth medium, mix 
thoroughly with a pipette and put solution in a 15 ml Falcon tube
5. Centrifuge at 500 rpm for 5 min
6. Suck off supernatant in order to remove the entire trypsin
7. Resuspend in growth medium, count the cell number and replate
Material: T75/T25 culture flask (Nunc, Denmark), pipette tips (Eppendorf, 
Germany), trypsin/EDTA-Solution (10x) (Cat. No. L11-003, PAA, Austria), 
Phosphate-buffered saline (PBS) w/o Ca²+, Mg²+ (Cat. No. H15-002, PAA) 
3.1.2.4. Determination and plating of a defined number of cells
Passaging, calculation of growth curves and other test procedures required the 
exact determination of cell number in cell solutions. Therefore as soon as the cells 
reached subconfluency they were trypsinized with 1x trypsin/ EDTA, stained by 
Trypan blue and counted with a Neubauer counting chamber. Trypan blue is a diazo 
dye and selectively colours dead cells blue, because it can not traverse the intact 
membranes of viable cells. The dye is used to distinguish viable from dead cells, so 
that the number of dead cells can be excluded.
After trypsinization, the cells were resuspended in growth medium (V: cell 
suspension volume). 50-100 μl of the cell suspension were transferred in a 1.5 ml 
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Eppendorf tube. Then 10 μl of the cell suspension was mixed with 5 μl of Trypan 
blue and 10 μl of this mixture was put under the cover glass of the counting 
chamber at the sample introduction point (see Figure 10). 
Cells were counted using a microscope (10x magnification) while blue cells were 
excluded. Cell numbers of quadrants 1, 2, 4 and 5 and on the upper and left border 
of 1, 2, 4 and 5 were added together.
 Cell number = [(1, 2, 4, 5)/4] × 10000 x 1,5 × V
                                                       
Figure 10. Improved Neubauer counting chamber, cover slip and counting grid with cells (Phelan 
2007, Current Protocols)
Material: Trypsin/EDTA (Cat. No. L11-003, PAA, Austria), Improved Neubauer 
counting chamber (Brand, Germany), 0.4 % Trypan blue (Gibco, Cat. No. 
15250-061, USA), tenocyte growth medium, Invert Microscope (Diavert, Leitz 
Wetzlar, Germany)
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3.1.2.5. Cryoconservation of cells
Tenocytes can be long-term cryopreserved by storing them in a freezer at -80° C 
or in liquid nitrogen at -196° C. For these purposes the cells were resuspended 
directly after passaging in a special pre-cooled freezing medium Table 3. 
Table 3. Freezing medium
Ingredients Concentration Company
Tenocyte growth medium 80 % see Table 2
Dimethylsulfoxide (DMSO) 10 % Sigma
Fetal bovine serum 10 % Sigma
The cell number in the freezing medium did not exceed 0,5 x 10⁵ - 1 x 10⁶ cells/ml. 
As a last step the solution was pipetted in 2 ml cryovials (Nalgene, USA), then stored 
at -20° C for 2 h and at -80° C over night. The cells were stored for different 
periods of time at -80° C or in liquid nitrogen.
3.1.2.6. Cell thawing
When cells had been cryoconserved and had to be thawed for plating and culturing, 
the vials were incubated in a preheated 37° C water bath until the solution was 
fluid. The cells were then transfered in 5 ml growth medium and centrifuged for 
5 min at 500 rpm. The supernatant was discarded and the cell pellet resuspended in 
5 ml growth medium. Finally, the cells were plated in a culture flask.
Material: Tenocyte growth medium, water bath (GFL, Germany), 15 ml Falcon tube
3.1.3. Calculation of cumulative population doubling
The long-term growth behaviour of tenocytes was investigated by counting their 
cell number and calculating the cumulative population doubling level (PDL). 
Population doubling (PD) was used to describe cell growth in a logarithmic mode. 
The population doubling that was gained at each passage was determined using the 
following formula:
PD = [log (Nn / No)] / log 2, or
PD = [log (Nn / No)] x 3.33
Nn = number of cells harvested at the end of a period of growth;
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No = number of cells plated initially in the growth vessel.
Cumulative population doubling level (PDL) is thus the sum of population doublings:
PDL n = Σ PD (1, n)
Population doubling time (PDT) is the period of time required for the cells to double. 
To calculate the PDT, the time period in which the cells are growing is divided by the 
population doubling value that is gained in the same time period.
PDT = (time period) / PD
3.2. Cell transduction by hTERT lentivirus
3.2.1. Lentivirus production and transduction of human cells
This part of the project was kindly carried out by Oliver Rossmann and Dr. Wolfgang 
Boecker in collaboration with Prof. Ulrich Koszinowski in the S2-laboratory facility of 
the Max von Pettenkofer-Institut of the University of Munich. To clone hTERT into 
the lentiviral vector the hTERT cDNA from pBABE-PURO plasmid was subcloned in 
pENTR11 plasmid (Invitrogen, Karlsruhe, Germany) by blunt end SalI/NotI ligation. 
Subsequently, the hTERT cDNA was transferred from pENTR11 into pLenti/V5-
DEST by recombination reaction using LRClonase according to the manufacturer’s 
protocol (Invitrogen). 
The correct sequence of the resulting pLentiV6/V5-hTERT was confirmed by 
sequencing (Sequiserve, Vaterstetten, Germany). Figure 11 shows schematically the 
lentiviral expression construct.
Figure 11. Plasmid chart of pLenti6/V5-hTERT (lentiviral expression construct). LTR: long terminal 
repeat, RRE: rev-responsive element, PCMV: CMV-promoter, PSV40: SV40-promoter, EM7: prokaryotic 
promoter, BSD: blasticidin resistance gene.
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Among the seven different tenocyte donors, two were selected, based on their 
morphology to be infected with hTERT. In the following scheme the basic principles 
of the infection are depicted (Figure 12). For the lentivirus production the 
ViraPower lentiviral expression system (Invitrogen) was used and carried out 
according to Boecker et al. 2007, J Gene Med. Briefly, plasmid DNA-Lipofectamine 
complexes were added to a 293FT cell suspension (23.76 x 10⁶ total cells) in a 
T-225 tissue culture flask. Two days after transfection, the virus-containing 
supernatant was harvested. The transduction of human tenocytes was 
accomplished with hTERT lentivirus (MDI: 5 x 10⁴) in the presence of 6 μg/ml 
polybrene (hexadimethrine bromide, Sigma). Afterwards the infected cells were 
selected by adding growth medium containing blasticidin (10 μg/ml). After 7 days 
of selection, the cells were cultured in normal tenocyte growth medium and the cell 
culture supernatant was tested to be viral particle free by p24 ELISA.
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Figure 12. Lentiviral production using a lentiviral vector. (A) Transfection. (B) Transduction. The 
details of each process are depicted in the figure.
Materials: 293FT cell line (Cat. No. R700-07; Invitrogen, Germany), ViraPower 
lentiviral packaging mix (Cat. No. K4975-00, Invitrogen), blasticidin S HCl 
(Invitrogen), 293FT culture medium [10 % (v/v) FBS ,1 % Pen/Strep, 0,1 mM MEM 
non-essential amino acids (Invitrogen) ad D-MEM (PAA)], tenocyte culture medium, 
Falcon tubes (Sarstedt), culture flasks (Nunc), Lipofectamine 2000 (Cat. No. 
11668-027, Invitrogen)
3.2.2. Single cell cloning
In order to obtain hTERT tenocyte clones out of the heterogeneous cell culture, 
single cell cloning was performed. Three different methods were applied:
Single cell picking: Five days prior to picking, cells were seeded at a concentration of 
75 cells per cm² in a T25 culture flask. At the beginning of the procedure 100 μl of 
medium was added to each well of a 6-well-plate. Cells were trypsinized for 5 min 
at room temperature and resuspended in 5 ml of medium. 1 ml of the suspension 
was further diluted in 9 ml of PBS (1:10 dilution). Subsequently, 5 ml of the dilution 
were pipetted into a 100 mm petri dish. Under a microscope single cells were picked 
with a 10 μl pipette (adjusted to 3 μl) and placed in the 6-well-dishes. 
The single cells were let to attach to the surface of the culture dish, 4 hours later the 
wells were controlled under the microscope and the region where the cell had 
attached was marked on the bottom of each well. Finally, 2 ml of medium was added 
to each well. This procedure was kindly performed by Tzvetan Popov.
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Colony forming: The cells were seeded at a very low density of 15 cells per cm2. 
Every day the dish was checked for single but dividing cells. As soon as a colony 
evolved from one single cell, a plastic ring was put around the colony and was locked 
into position with sterilized Vaseline. The colony in the ring was then trypsinized and 
moved in a well of a 6-well-plate for further expansion.
Serial dilution: Briefly, this method is based on an increasing dilution of a tenocyte 
cell suspension, until 1 cell/200 μl is obtained and it is placed in one well of a 96-
well plate. For further details see the protocol below:  
1. Remove culture medium and wash cells with 5 ml PBS per T-75 flask. 
2. Trypsinize cells with 2 ml 1x Trypsin/EDTA solution for 5 min at RT. 
3. Take up the cells with 5-6 ml culture medium and resuspend well in 50 ml Falcon tube 
-> solution S (starting solution). 
4. Count cells as described in 3.1.2.3.
5. Dilute solution S to 1000 cells/ml in a new 50 ml Falcon tube -> solution A (include an 
additional dilution step of 1:10 if the number of cells in solution S exceeds 100 000/ml 
-> Solution S1).
6. In a new 15 ml Falcon tube add 1 ml of solution A to 9 ml of culture medium (1:10 
dilution) to achieve a cell concentration of 100 cells/ml -> solution B.
7. In a new 50 ml Falcon tube add 2 ml of Solution B to 38 ml of culture medium (1:20 
dilution) to achieve a cell concentration of 5 cells/ml = 1 cell/200 μl -> solution C
8. Transfer solution C to a reagent basin and with the help of a multi-channel pipette, add 
200 μl of the solution to each well of the 96-well dish. Retain well A1 (positive control) to 
add non diluted cell suspension for the adjustment of the microscopic level during the 
observation of the plate.
9. Grow cells in cell culture incubator under standard conditions.
10. The 96-well plate can be examined the day after. Wells with one cell are identified and 
marked. Cells from these wells are expanded as an individual clones.
Materials: 6-well-plate (Nunclon, Denmark, Cat. No. 140675), 96-well-plate 
(Nunclon), 15 and 50 ml Falcon tubes, 1x trypsin/EDTA-solution PBS, vaseline, 
plastic rings, 100 mm and 60 mm petri dishes, reagent basin, multi-channel pipette, 
10 μl and 200 μl pipette tips, cell counting materials
34
3.3. Methods for analysis
3.3.1. RT-PCR
3.3.1.1. RNA isolation
The RNA isolation was performed following the standard protocol from Qiagen 
(RNeasy Mini Handbook 04/2006) using the provided materials in the RNeasy Mini 
Kit from Qiagen. As recommended in the handbook cells were lysed with 600 μl lysis 
buffer per T75 at a confluency of approximately 80 - 90 % then scraped from the 
surface of the culture flask and thoroughly mixed with the buffer. Not more than 1 x 
106 cells were used for the procedure.
Material: RNeasy Mini Kit (Cat. No. 74106, Qiagen, USA), cell scraper (Sarstedt), 
lysis buffer (Buffer RLT + 14.3 M β-mercaptoethanol)
 3.3.1.2. cDNA Synthesis
For cDNA synthesis the Cloned AMV First-Strand cDNA Synthesis Kit for RT-PCR 
from Invitrogen was used. The procedure was carried out according to the 
manufacturers instructions. 1 μg of total RNA was used for cDNA synthesis and a 
volume of 20 μl cDNA solution was obtained.
Material: Cloned AMV First-Strand cDNA Synthesis Kit (Cat. No. 12328-040, 
Invitrogen), PCR thermocycler PTC-200 (Bio-Rad, Germany)
 3.3.1.3. Polymerase chain reaction
For Polymerase chain reaction primer sequences were either self-designed with the 
Clone Manager program (Scientific & Educational Software, USA) or adopted from 
publications. 
The primers were ordered from Invitrogen diluted to a concentration of 10 pmol/μl. 
The components of a basic PCR set up are depicted in Table 4.
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Table 4. PCR components
Reagent Volume per sample (μl)
10x Puffer 2
MgCl 0,6
dNTP 0,4
Primer forward 0,5
Primer reverse 0,5
Q-Solution 4
Taq Polymerase 
(Cat. No. 10342-020, Invitrogen)
0,2
H₂O 10,8
cDNA 1
Table 5. Standard PCR program (the steps in the box were repeated for 30-40 cycles)
Temperature Time Step
95°C 3 min denaturation
95°C 30 sec
45-65°C 30 sec annealing
72°C 1 min elongation
72°C 10 min
4°C forever
The PCR was performed in the PCR thermocycler PTC-200 using standard PCR 
program (Table 5). The program (annealing temperature and cycle number) was 
adapted individually for each primer set (Table 6). 
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Table 6. Primer sequence and reaction conditions
Target gene Primer (forward/reverse) Annealing temp.(°C)
Product size 
(bp) Cycles Reference
Collagen I 5’-CCAGTCACCTGCGTACAGAA-3’ 54 223 40 Gronthos et al. 
2006
5’-GAGACCACGAGGACCAGAAG-3’
Collagen III 5’-CCC ACT ATT ATT TTG GCA CAA 
CAG-3’
50 99 38 Shigeyama et 
al. 2005
5’-GCA TGG TTC TGG CTT CCA GA-3’
COMP 5’-GCT CTG TGG CAT ACA GGA GA-3’ 53 145 40 Tian et al. 2006
5’-CAT AGA ATC GCA CCC TGA TG-3’
Decorin 5’-GCT GGA CCG TTT CAA CAG AGA G-3’ 54 437 40 Chung et al. 
2002
5’-TCA TTC TCA TGG GCA CGC AG-3’
EphA4 5’-CCA ACC AAG CAG TGC GAG AG-3’ 54 385 35 self-designed
5’-CCA GAC CCA ATG CCA CGA AG-3’
Eya1 5’-GTT CAT CTG GGA CTT GGA-3’ 46 229 40 Okada et al. 
2006
5’-GCT TAG GTC CTG TCC GTT-3’
GAPDH 5’-CAA CTA CAT GGT TTA CAT GTT C-3’ 50 181 30 Takahashi et al. 
2003
5’-GCC AGT GGA CTC CAC GAC-3’
hTERT 5’-CTA CGG CGA CAT GGA GAA C-3’ 54 413 35 Boecker et al. 
2008
5’-GAC ACT TCA GCC GCA AGA C-3’
Scleraxis 5’-CCT GAA CAT CTG GGA AAT TTA ATT 
TTA C-3’
48 294 38 Schulze-Tanzil 
et al. 2004
5’-CGC CAA GGC ACC TCC TT-3’
Six1 5’-TGC TTG TTG GAG GAG GAG TT-3’ 55 206 35 Ng et al. 2006
5’-AAG GAG AAG TCG AGG GGT GT-3’
Tenascin C 5’-GAG AAA GGC AGA CAC AAG AG-3’ 57 395 35 self-designed
5’-GCA GTC CAG TTG AGT TTG AG-3’
Tenomodulin 5’-GGA TAC ACT GGC ATC TAC TTC G-3’ 48 381 45 self-designed
5’-GTG ACG GGT CTT CTC TAC TTT C-3’
3.3.1.4. Agarose gel electrophoresis
For analysis of PCR products gel electrophoresis was used. Agarose gels (0,8 – 
1,2 %) were produced and 6 μl of ethidium bromide dye was added. The solid gel 
was covered with TAE buffer. The PCR samples (20 μl) were mixed with 6x Orange 
loading dye, loaded on the gel and run at 100 V current. Ethidium bromide 
intercalates into DNA and allows visualization of the separated PCR fragments. After 
the electrophoresis, the gel was pictured with a gel imager (Transilluminator, Vilber 
Lourmat, Germany).
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Material: Agarose (Biozym Scientific, Germany), TAE buffer 50x [242 g/l tris-base, 
57,1 ml/l acetic acid, 100 ml/l EDTA (500mM, pH 8,0)], ethidium bromide (Merck), 
6x Orange loading dye (Fermentas, Canada), 100 bp DNA ladder (Invitrogen), gel 
chamber (Peqlab, Germany), machine for electrophoresis (Consort E132, Peqlab)
3.3.2. Immunocytochemistry
3.3.2.1. Fixation of cells
Cells were cultivated in plastic chambers affixed to a glass microscope slide. When 
the cells had grown to the desired confluency (50-60 %) they were fixed with 
100 % methanol. Tenocyte growth medium was sucked off, the cells were washed 
with 2 ml of PBS and 2 ml of methanol was added for 10 min at -20° C. Afterwards 
the cells were washed with PBS for 10 min at room temperature. Finally, the 
methanol was removed and the slide with the cells was dried at room temperature. 
The fixed cells were then stained immediately or stored at -80° C.
Material: BD Falcon CultureSlides, methanol (Merck, Germany), PBS 
3.3.2.2. Immunofluorescence
The slides were subdivided into fields using a Dako pen. Thus, different 
concentrations of primary antibody were applied and part of the slide was used as a 
negative control where only secondary antibody was applied. The staining is 
described below:
1. Rehydrate cells 5 min in PBS supplemented with 0.1 % Tween
2. Blocking with 3 % bovine serum albumin (BSA) in PBS for 60 min at room temperature
3. Remove blocking solution by tapping it off
4. Application of primary antibody Anti-hTERT 1:10 in PBS (200 µl per field); negative 
control just with PBS or blocking solution
5. Incubate over night at 4° C in humidified chamber
6. Wash 3x5 min in PBS supplemented with 0.1 % Tween 
7. Application of secondary flourescent antibody (diluted in PBS) – Alexa 546 1:500
8. Incubate for 60 min at room temperature in a humidified dark chamber
9. Wash again 3x5 min in PBS supplemented with 0.1 % Tween
10. Application of 200 μl DAPI (1:10000 dilution with aqua dest.; nuclear staining)
11. Incubate for 1 min at room temperature protected from light
12. Wash 2x5 min in PBS supplemented with 0.1 % Tween
13. Place mounting medium on the slide and with the help of a preparative needle put the 
cover glass in place (try to avoid trapping of bubbles). Keep the slides at 4° C 
14. Perform microscopical analysis and take photographs
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Material: Histological jars, primary antibody: Anti-hTERT (348-358) Rabbit pAB 
(Calbiochem, Germany, Cat.No.PC563), secondary antibody: Alexa Fluor 546 goat 
anti rabbit (Invitrogen, Cat.No.A11035), Dako pen (Dako, Denmark), 3 % BSA (0,3 
g/100 ml; Sigma), DAPI (4,6-diamino-2-phenylindole, dihydrochloride; Molecular 
Probes), Tween 20 (Merck, Germany), mounting medium (6 g glycerin, 2.4 g 
Mowiol 4-88 (Calbiochem), 6 ml aqua dest., 12 ml 0.2 M Tris pH 8.6, 0.024 g, 
1,4-Diaza-bicyclo[2.2.2]octane (DABCO; Fluka, Germany), Axioskope microscope 
(Carl Zeiss MicroImaging GmbH, Germany)
3.3.3. Senescence-associated β–galactosidase assay
In order to detect β-galactosidase activity a Senescent Cells Staining Kit (Sigma) 
was used. The histochemical stain is based on the artificial substrate X-gal that 
forms a local blue precipitate upon cleavage with β-galactosidase at pH 6 (Itahana 
et al. 2007). For this experiment untransduced tenocytes, hTERT-transduced 
tenocytes and hydroxyurea-treated hMSCs (positive control) were used. Yeo et al. 
2000 positively tested hydroxyurea as an inductor of senescence in vitro. During 
H2O2-dependent peroxidation of hydroxyurea, NO is generated which inhibits 
ribonucleotide reductase and as a consequence of this a lack of deoxynucleotides 
required for DNA sythesis. In the end this results in DNA single strand breaks leading 
to cell cycle arrest (Sato et al. 1997, Jiang et al. 1997, Mata et al. 1989). HMSC 
were treated with 2 mM hydroxyurea in growth medium for 48 hours according to 
Yeo et al. 2000.
Operating procedure:  
1. Aspirate the growth medium from the cells (6 well dish, 60 % density).
2. Wash the cells twice with 1 ml of 1x PBS per well. 
3. Add 1.5 ml of 1x Fixation Buffer per well and incubate the plate for 6–7 minutes at room 
temperature.
4. Rinse the cells 3 times with 1 ml of 1x PBS per well.
5. Add 1 ml of the Staining Mixture per well. Incubate at 37° C without CO₂ for 
approximately 12 hours. 
6. Replace Staining Mixture with 70 % glycerol solution and seal the plate with Parafilm to 
prevent it from drying out.
7. Observe cells under a microscope, count all blue stained cells as well as the total number 
of cells and take example pictures.
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Material: Senescent Cells Staining Kit (Sigma, Cat. No. CS0030, USA)
Fixation Buffer 10x (Product Code F 1797) Solution containing 20 % formaldehyde,
2 % glutaraldehyde, 70.4 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M NaCl, and 
26.8 mM KCl, Reagent B (Product Code R 5272) 400 mM Potassium Ferricyanide, 
Reagent C (Product Code R 5147) 400 mM Potassium Ferrocyanide, X-gal Solution 
(Product Code X 3753) 40 mg/ml, Ultrapure water (Sigma, Cat. No. W3500-1L, 
USA), 6 well plate (Nunclon, Denmark, Cat. No. 140675), PBS, hydroxyurea 
(Sigma), hMSC growth medium AlphaMEM (Invitrogen)
3.3.4. Telomerase activity test
To demonstrate the telomerase activity in hTERT-transduced tenocytes, a 
photomeric enzyme immunoassay for quantitative determination of telomerase 
activity (Telo TAGGG Telomerase PCR ELISAPLUS, Roche; Figure 13) was utilized.
1. Telomerase adds telomeric repeats (TTAGGG) to the 3’ end of the biotin-labelled 
synthetic P1-TS-primer (artificial template). 
2. Elongation products are amplified by PCR using the primers P1-TS and P2, generating 
PCR products with the telomerase specific 6 nucleotide increments. 
3. An aliquot of the PCR product is denatured and hybridized to a digoxigenin-(DIG)-
labelled, telomeric repeat-specific detection probe. 
4. The resulting product is immobilized via the biotin labelled primer to a streptavidin-
coated microplate. The immobilized PCR product is then detected with 
an antibody against digoxigenin (anti-DIG-POD) that is conjugated to peroxidase. 
At last, the peroxidase metabolizes TMB (3,3’,5,5’-tetramethylbenzidine) in order to form a 
coloured reaction product. The extinction can be measured at 450 nm (with a reference 
wavelength of approximately 690 nm).
Figure 13. Scheme of the different steps of the telomerase activity test. TRAP: Telomeric 
Repeat Amplification Protocol - the telomerase-reaction product is amplified by PCR (Roche 
Applied Science, Cat. No.11854666910 2008)
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All procedures of the assay were carried out accurately following the protocol 
provided by the company. Measurements were performed in triplets.   
A pellet of 2 x 105 cells (HTD2, HTD5, HTD2 hTERT and HTD5 hTERT, all at passage 
10) was used per single reaction. After washing in PBS the cell pellet was 
resuspended in 200 μl of lysis reagent before performing the TRAP reaction from 
3 μl of the cell extract. 293FT cells served as a positive control as this is a 
permanent cell line (established from primary embryonal human kidney transformed 
with sheared human adenovirus type 5 DNA) and exhibits a high telomerase activity 
(Graham et al. 1977).
Materials: Telo TAGGG Telomerase PCR ELISAPLUS (Roche Applied Science, 
Cat. No.11854666910, Germany), ELISA reader (Microtek Laborsysteme GmbH, 
Germany)
3.3.5. Soft agar assay
The soft agar assay was performed according to Boecker et al. 2008 using 6-well 
plates. In total 4 x 2500 cells per donor were seeded. HT1080 cells (fibrosarcoma 
cell line) were employed as positive controls and untransduced tenocytes as 
negative controls.
1. Prepare 0.5 % base agar solution: mix DMEM/tenocyte culture medium (+ 20 % FBS) 
with agarose and microwave until the agarose has dissolved. Let it cool down in water bath 
at 40°C.  
2. Fill in 6-well plate (1 ml/well).
3. Prepare 0.35 % top agar solution: mix DMEM/tenocyte culture medium (+ 20 % FBS) 
with agarose and microwave until the agarose has dissolved. Let it cool down in water bath 
at 37°C.
4. Trypsinize and count cells, harvest 2500 cells/well.
5. Resuspend harvested cells in 0.35 % top agar solution (37° C) and aliquot on top of base 
agar layer (0.5 ml/well). 
6. Incubate cells for 28 days at 37° C with 5 % CO₂.
7. Feed cells 1-2 times per week with 0.5 ml of culture medium per well.
8. After 28 days stain colonies with 0.005 % crystal violet for 1 h.
9. Observe cells under a microscope, count cells/colonies and take pictures.
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Material: agarose (Biozym Scientific), 6-well-plates (Nunclon), tenocyte growth 
medium, DMEM culture medium (PAA), FBS, crystal violet (Sigma), light microscope 
(Axiovert 100, Carl Zeiss), water bath (GFL, Germany), microwave (Siemens, 
Germany)
3.4. Microscopy
Cell morphology was observed throughout the culture period by the inverted 
phase-contrast microscope Axiovert S100 (Carl Zeiss, Germany). 
Immunocytochemistry was analysed with the epifluorescence microscope 
Axioskope2 (Carl Zeiss). Images were acquired with a Zeiss black and white digital 
camera (AxioCam MRm; 1388 x 1040 pixels) and processed with the Zeiss 
AxioVision software (AxioVs40 V 4.7.1-08-2008).
3.5. Statistical analysis
Statistical analysis was performed using SigmaPlot version 8 (SPSS, Germany). 
Significances were calculated using Student’s t-test. A value for P < 0.05 was 
considered significant.
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4. RESULTS
4.1. Primary culture of tenocytes
4.1.1. Tendon donors
The properties of the tendon donors, such as the age of the patients, the type of 
tendon and the size of the sample are shown in Table 7. An anonymisation of the 
samples was implemented, giving each a new specific identification code: HTD, with 
H standing for human, T for tendon and D for donor. In total 10 specimens were 
obtained but only from 7 donors we gained cells. Two donors were used in the 
following part of the study (HTD2 and HTD5).
Table 7. Donor properties
Donor Age Type of tendon Size [mm]
HTD2 58 Flexor tendon toe 2x5 
HTD3 43 Flexor tendon toe 3x10 
HTD4 62 Extensor hallucis longus 4x15 
HTD5 60 Achilles tendon 5x15 
HTD6 62 Flexor tendon toe 4x20 
HTD7 52 Peronaeus longus 10x15 
HTD9 50 Cruciate ligament 15x10 
4.1.2. Tenocyte outgrowth and tendon digestion
Approximately 14 days after plating the tendon pieces in culture dishes, tenocytes 
started to migrate out (Figure 14). Once the area around the tendon pieces was 
filled with a dense layer of cells, the tissue was removed from the culture dishes. 
Subsequently, the adherent cells in the dish were trypsinized and replated after 
counting in a cell culture flask (T25) at a density of around 1000 cells/cm². Further, 
the cells were cultivated and passaged as shown in 3.1.2.2. 
Figure 14. Culture dish with tendon pieces (A and B) and outgrowth of tenocytes (C).
43
The digestion of tendon tissue allowed the extraction of tenocytes within a period 
of approximately 4 hours. However, the cells were less homogeneous than the ones 
gained by outgrowth. We therefore refrained from using the cells extracted from the 
tendon tissue by digestion for further investigation.    
4.2. hTERT-expression
4.2.1. hTERT RT-PCR
Lentiviruses containing the gene of hTERT were generated from the lentiviral 
expression construct pLenti6/V5-hTERT. The pLenti6/V5-DEST-vector contains a 
blasticidin resistance gene for blasticidin-S deaminase allowing a selection of 
transduced cells, proving the successful infection. At passage 4 two donors, HTD2 
and HTD5, were infected. 
Analyzing the infected cells on RNA-level principally proved the successful outcome 
of the HTERT-transduction of the primary tenocytes. To assess the functionality of 
the inserted gene, overexpression of hTERT in tenocytes was also proven on a 
protein level. First, the hTERT expression was proven by RT-PCR in both donors 
(HTD2 hTERT and HTD5 hTERT). 
To show that the transduced tenocytes do not lose the hTERT transgene over time, 
hTERT-tenocytes at passage 8 and 16 were tested as well. In the RT-PCR, at both 
time points a strong expression of hTERT mRNA was detected in hTERT-transduced 
tenocytes, while no hTERT expression was detected in untransduced tenocytes 
(Figure 15).
Figure 15. hTERT expression was detected in hTERT-transduced tenocytes, but not in untransduced 
control tenocytes.
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4.2.2. hTERT immunocytochemistry
Using immunocytochemistry the expression of hTERT was proven on a protein level 
(Figure 16).
Figure 16. Immunocytochemical staining of HTD5 (p 9) and HTD2 hTERT (p 10) and HTD5 hTERT 
(p9). A, B, C phase contrast and DAPI nuclear staining (blue). D, E, F hTERT staining (green). 
Secondary antibody: Alexa 546 goat anti rabbit. 
Bar: 100 μm.
HTERT protein was primarily located within the nucleus of the hTERT-transduced 
tenocytes, while no hTERT expression was detected in untransduced control 
tenocytes.
4.2.3. Analysis of telomerase activity
The telomerase activity assay revealed consistent results with RT-PCR and 
immunocytochemistry. HTD2, HTD5, HTD2 hTERT and HTD5 hTERT (2 x 105 cells, 
all passage 10) were tested for telomerase activity with a photomeric enzyme 
immunoassay (Figure 17). 
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Figure 17. Telomerase activity assay. HTERT-tenocytes (HTD2 hTERT and HTD5 hTERT) have 
significant higher relative telomerase activity (P < 0,05). Untransduced tenocytes (HTD2 and HTD5) 
show merely a background level of telomerase activity. 293 FT cells: positive control. Error bars: 
standard mean of samples in triplicates.
The results demonstrate that untransduced human tenocytes had only background 
levels of telomerase activity, while hTERT-overexpressing cells showed significantly 
higher levels of telomerase activity. 293FT cells served as positive control.
4.3. Single cell cloning
In order to obtain a single cell-derived tenocyte cell line, three different methods 
were applied: single cell picking, colony forming unit assay and serial dilution. Under 
standard culture conditions isolated tenocyte clones did not proliferate (see Table 8). 
Therefore different approaches were used to improve the attachment, growth and 
survival of single cells:
As a first approach FBS was increased to 20 % in tenocyte culture medium in order 
to supply the single cell with more nutrients. Another strategy was coating the 
surface of the culture dishes with type I collagen (approximately 4 μg/cm2) in order 
to aid adherence of the single cell. Thirdly, a special 6-well culture dish insert was 
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implemented. The insert has a porous ground area on which cells adhere while 
factors that are excreted by the cells can pass the membrane and are dissolved in 
the medium. Thus, certain (growth) factors secreted by a heterogeneous hTERT-
transduced tenocyte population can reach the single cell on the bottom of the well 
(Figure 18).
Figure 18. Scheme of culture dish inserts. A single cell was picked and seeded on the bottom of a 6-
well culture dish. Heterogeneous tenocytes were seeded on the insert. The well is filled with culture 
medium. 
Table 8. Summary of single cell cloning
Method Nr. of experiments Efficiency Clonal production(>12 cells)
Clonal production
 (< 12 cells)
Single cell picking 5 (206 single cells picked) > 85 % none 10
Colony forming 3 - none none
Serial dilution 3 45 % none 5
All runs of single cell picking, colony forming and serial dilution experiments did not 
lead to a proliferating single cell clone. If the cells divided at all, they ceased to 
proliferate after 2-3 divisions (Table 8). After approximately 14 days the cell 
morphology changed from laterally stretched and spindle shaped to round and 
flattened before the cells detached.
4.4. Growth kinetics
Whereas both donors of the tissue samples were almost the same age the disparity 
of tendon type and sex might lead to different growth behaviour. The growth 
characteristics of heterogeneous hTERT-expressing human tenocytes (HTD2 hTERT 
and HTD5 hTERT) and untransduced human tenocytes (HTD2 and HTD5) during 
prolonged culture were monitored, by calculating the population doubling level 
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(PDL). Both untransduced donors showed initially a higher proliferation rate than the 
hTERT-tenocytes. After 18 (HTD2) and 9 (HTD5) PDL the growth curve reached a 
plateau phase indicating the transition into a senescent state. The proliferation rate 
of hTERT-transduced tenocytes in the beginning was lower (12 PDL HTD2 hTERT 
and HTD5 hTERT) but both donors continued to proliferate for a time period of 300 
days (Figure 19 and Figure 20).
Figure 19. Growth curve of HTD2 and HTD2 hTERT. Complete growth arrest and senescence of 
HTD2 cells after around 160 days.
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Figure 20. Growth curve of HTD5 and HTD5 hTERT. Complete growth arrest and loss of HTD5 cells 
after 100 days.
4.5. Cell morphology of primary and hTERT-transduced cells
The cell morphology of hTERT-expressing and control tenocytes was monitored 
throughout the culture period as cells were photomicrographed regularly (Figure 
21). For a better classification the individual cell passages were linked to three 
growth stages: early (≤10 passages), middle (11-19 passages) and late (≥ 20 
passages).
Human tenocytes in early passages appeared thin, bi-polar and spindle-shaped. 
During prolonged culture, the cell shape changed into a flat and outstretched 
appearance suggesting that the cells underwent senescence. The untransduced 
human tenocytes started to alter their morphology at 8 (HTD5) or 18 (HTD2) PDL 
respectively. In contrast HTD2 hTERT and HTD5 hTERT retained a spindle-shaped 
appearance for nearly one year (12 PDL). At the end of this period hTERT-
transduced tenocytes altered their morphology from a slender spindle-shaped form 
to a more flattened appearance, while at the same time, their growth capacity 
decreased markedly (Figure 22). 
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Figure 21. Cell morphology at different phases: early, middle and late. (A and E) early untransduced 
tenocytes (B and F) early, (C and G) middle, (D and H) late passages of hTERT-transduced tenocytes. 
10x magnification. Bar: 100 μm.
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Figure 22. Senescence-associated morphological changes in untransduced and transduced tenocytes. 
(A and C) untransduced tenocytes which exhibited senescence features already at passage 13. 
HTERT-transduced tenocytes showed cell flattening at passage 28 (B and D). 10x magnification. Bar: 
100 μm.
4.6. Senescence analysis
In order to objectify senescence of the cells a specific assay, the β-galactosidase 
assay, was performed. With the β-galactosidase assay senescent cells can be 
distinguished from viable, quiescent, tumourigenic or immortal cells. For the 
experiment 20000 cells of HTD2, HTD5, HTD2 hTERT, HTD5 hTERT and control 
hMSC per well (6-well plate) were seeded and cultivated for 7 days. 48 hours prior 
to the staining, control hMSCs were treated with 2 mM hydroxyurea (HU; Figure 
23).
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Figure 23. Senescence associated β-galactosidase assay. Blue cells are senescent cells (examples →). 
A and D depict untransduced tenocytes with pronounced 
β-galactosidase activity at passage 18. B and E show hTERT-transduced tenocytes with almost no 
β-galactosidase activity at passage 20. HU- treated hMSCs: positive control (C). 10x magnification. 
Bar: 100 μm.
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Figure 24. Quantification of the senescence associated β-galactosidase assay. 
A: Donor 2. B: Donor 5. Untransduced tenocytes (white bars) had noticeably more 
β-galactosidase positive cells compared to hTERT-tenocytes (black bars). Positive control: 
hydroxyurea pretreated human mesenchymal stem cells (hMSC-HU; grey bars). Error bars: standard 
mean of samples in triplicates.
Untransduced human tenocytes exhibited significant senescence-associated 
β-galactosidase activity similar to the positive control around passage 18. In 
contrast, introducing hTERT into human tenocytes resulted in an extension of their 
lifespan as seen in their growth curve over time. Moreover, this was reflected by the 
lack of detectable senescence-associated β-galactosidase activity even at late 
passages (passage 20; Figure 24).
4.7. Tendon-related gene expression
Tendon-related gene expression was investigated by RT-PCR and served to confirm 
that the hTERT-transduced tenocytes did not loose their tenogenic nature during 
prolonged culture time. 
Therefore, a combination of tendon specific gene markers was selected (Figure 25). 
These markers were sub-divided into three groups: A) fibrillar proteins (collagen I, 
collagen III), B) matrix proteins (Decorin, Tenascin C, COMP and TNMD) and C) 
transcription factors (Six 1, EphA4, Eya 1). All markers were tested at two different 
passages (early and middle) by PCR for untransduced tenocytes HTD2 p4 and p15, 
HTD5 p4 and p12 and hTERT-transduced tenocytes HTD2 hTERT p 8 and p 16, 
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HTD5 hTERT p8 and p15. Some markers were strongly expressed in early passages 
(e.g. Eya 1, EphA4), others in middle passages (e.g. Decorin, COMP). Both cell types 
showed no downregulation of genes over prolonged in vitro passaging. Among all 
genes tested only TNMD mRNA was not expressed after passage 1 (see 4.8.).
Figure 25. Tenogenic profile of HT D2 hTERT, HT D5 hTERT, HT D2 and HT D5 (early: ≤10 passages, 
middle: 11-19 passages). (A) fibrillar proteins, (B) matrix proteins and (C) transcription factors.
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4.8. Long-term high density culture
Cells cultured over long periods of time started to rearrange themselves within the 
culture dishes. After 30-40 days the previously exclusively two-dimensional growth 
pattern turned into the formation of three-dimensional strands (Figure 26 A). 
Furthermore, after 90 days in culture, the cells started to deposit matrix within the 
culture dishes. 
Tenomodulin is expressed in the first cell passage (HTD7 p1) and afterwards it is 
rapidly lost (HTD5 hTERT p5). Interestingly, after 90 days in high density culture, 
tenomodulin expression can be detected again by RT-PCR (HTD5 hTERT p5 90d; 
Figure 26 B).
Figure 26. Long term high confluence culture. (A) Cell morphology after 40 and 90 days. (B) 
Tenomodulin expression. Human tendon (htendon) served as positive control. Bar: 100 μm.
4.9. In vitro tumourigenicity analysis
To evaluate the tumour forming potential of hTERT-transduced human tenocytes a 
functional in vitro assay was performed (Figure 27). Tumour cell lines like HT1080 
are, amongst other things, characterized by the loss of anchorage dependency. This 
is a key feature of neoplastic transformation. Therefore, cancer cells like HT1080 are 
able to form colonies when seeded in soft agar and served as a positive control in 
this assay. 
55
Figure 27. Soft agar assay. Colony forming of control tumour cell line HT1080 (A). No colonies 
formed in hTERT-transduced tenocytes (B and C). Bar: 100 μm.
In this investigation the top agar was inoculated with 2500 cells of HTD2 hTERT 
p20 and HTD5 hTERT p28 per well. After 28 days the tumour cell line HT1080 had 
formed colonies, while hTERT-immortalized tenocytes showed contact inhibition 
and remained single cells. This indicates that hTERT-immortalized cell lines did not 
undergo malignant transformation in vitro.
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5. DISCUSSION
Tendinous tissue and its interaction with adjacent tissues like bone or muscle is a 
complex subject. Not only that the embryonic development of tendon is still poorly 
understood but also, clinically more relevant, there is not much known about tendon 
pathology and possible treatment strategies in case of tendinopathy or tear. 
Research concerning tendon repair is only standing at the beginning of the 
possibilities that are arising from tissue engineering and cell- and gene-based 
therapy. These new approaches need suitable, stable and quite a number of cells to 
work with in a rather short time span so that they are actually applicable for clinical 
use. Therefore, a human tenocyte cell line, allowing long term molecular 
characterization in vitro and leadoff studies for clinical and therapeutic applications, 
is needed.
Isolation of tenocytes – Tenocyte outgrowth and tendon digestion
The isolation of tenocytes was one of the first milestones in this project. Two 
methods of tenocyte extraction are known: first, digestion of the tendon tissue with 
collagenase and second, culturing explants of human tendon in culture dishes until 
the cells actively migrate from the tendon tissue. Collagenase digestion was 
performed by Salingcarnboriboon et al. 2003 with Achilles tendon of transgenic 
mice. The second technique, tenocyte outgrowth, was applied by Schulze-Tanzil et 
al. 2004 and Fu et al. 2007 using human tendon and rat patellar tendon, 
respectively. For tissue engineering applications the time in which the cells can be 
obtained and expanded plays a significant role. Schulze-Tanzil et al. demonstrated 
that the cells started to migrate out of the tissue after 1-2 weeks while it took even 
more days until they formed a monolayer that could be trypsinized and further 
expanded. Besides digesting the tendon tissue with collagenase is not only faster but 
as well more cells at once can be gained. On the other hand one could speculate that 
the cells that are able to actively migrate out of the tendon are viable and healthy 
and therefore more suitable for further implementation in tissue engineering. 
Furthermore, the treatment of the cells with collagenase over a prolonged period of 
time might cause cellular damage. In this project both methods were applied without 
any difficulty. In general, it has to be decided on an individual basis which method is 
the most convenient. For us the viability of the cells was crucial and we therefore 
immortalized cells gained by the outgrowth method.
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Immortalization of cells – hTERT transduced tenocytes avoid senescence
In this project novel tendon-derived cell lines were established and they stably 
expressed hTERT on RNA and protein level as well as they showed a significant 
telomerase activity (Figure 16 and Figure 17). 
New approaches in tendon repair, like tissue engineering and cell-based gene 
therapy rely on constituent cells to work with. Unfortunately the availability of 
tenocytes that could substitute damaged or diseased tendon tissue is limited. 
Theoretically, extracting the tenocytes, expanding them in vitro, processing them 
further and re-implanting the cells, could solve this problem. However, there are 
some aspects that contradict this theory. First the cell number is generally limited, 
secondly their proliferation in vitro often leads to dedifferentiation and thirdly in 
vitro culture conditions frequently result in senescence-associated growth arrest 
(replicative senescence) and finally cell death (Stenderup 2003).  
One possible solution to this problem could be the immortalization of cells. Each cell 
division leads to telomere length shortening of chromosomes, which can be the 
cause of replicative senescence (Wright and Shay, 1992). Telomerase can 
synthesize telomeric repeats and therefore extend cellular lifespan. Primary 
tenocytes show no telomerase activity in vitro (Figure 17) and therefore ectopic 
expression of hTERT in tenocytes can prevent replicative senescence. In our study 
HTD2 hTERT and HTD5 hTERT cell lines showed an extended lifespan compared to 
untransduced tenocytes (see 4.4). Many other groups have shown the feasibility of 
cellular lifespan extension for e.g. human endothelial, fibroblast and oesophageal 
squamous cells by using hTERT gene therapy (Bodnar et al. 1998, Hahn et al. 1999, 
Yang et al. 1999, Morales et al. 2003, Cheung et al. 2010). However, when cells are 
generally modified it is important that not only the immortalization or transgene 
expression is ensured but also that the cells retain their (tenocyte) character.
Another method successfully used for immortalization of cells is the overexpression 
of SV40 large T antigen gene. Salingcarnboriboon et al. 2003 isolated tenocytes 
from Achilles tendon of transgenic mice harbouring the SV40 large T antigen gene. 
The authors were able to culture the harvested cells for more than one year. One 
important difference between the two mentioned genes is that the SV40 large T 
antigen gene interferes with the cell cycle making it more prone to malignat 
transformation. SV40 large T antigen is a primary viral gene product that is involved 
in both viral replication and SV40-mediated cell transformation. It promotes 
transformation by binding and inactivating the products of a number of tumour 
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suppressor genes, which include p53 and pRb. And it also stimulates cell proliferation 
by promoting cell-cycle progression from G1 to S phase (Carbone et al. 1997, 
Fanning et al. 1992).
Contrary to SV40, hTERT does not cause growth deregulation (Harley 2002; Lee et 
al. 2004; Toouli et al. 2002). Still it has to be considered that neoplastic 
transformation was reported for hTERT-transduced adult MSC after prolonged in 
vitro culture (Serakinci et al. 2004). Yet most of the cases reported with neoplastic 
transformation of immortalized cells depended largely on the viral vector used. 
Montini et al. 2006 compared the tumourigenic potential of retroviral vectors and 
lentiviral vectors. They observed that retroviral vectors triggered dose-dependent 
acceleration of tumour onset contingent on long terminal repeat activity. 
Furthermore, insertions at oncogenes and cell cycle genes were enriched in early 
onset tumours, indicating involvement in tumourigenesis. Contrary to these findings, 
tumourigenesis was unaffected by lentiviral vectors and did not enrich for specific 
integrants (Burns et al. 2005). This suggests that in the case of hTERT not the insert 
itself leads to neoplastic transformation but more likely the retroviral vector.
Recently, Boecker et al. 2008 have reported the successful immortalization of 
human MSC via lentiviral gene transfer of hTERT. These cells showed no sign of 
replicative senescence in vitro with ‚significantly higher and unlimited proliferation 
capacity’ and ‚preserved their stem cells character as shown by osteogenic, 
adipogenic and chondrogenic differentiation’. At the same time the clones did not 
undergo malignant transformation, as confirmed by in vitro and in vivo assays. Based 
on their results in this project the same approach was used and carried out 
successfully in human tenocytes. 
Single cell cloning - The establishment of a single tenocyte-derived cell line under 
standard culture conditions was not feasible
Primary cell cultures derived from different tissue types are often heterogeneous in 
standard conditions as they may contain more than one cell type. To ensure that 
there is no variation in cell culture characteristics and to obtain a homogeneous cell 
culture a single cell-derived cell line is most suitable for long term in vitro studies. 
Cell cloning is therefore an effective way to ensure the purity of a cell line. Many 
strategies of single cell separation have been reported. So far the most common 
ones are: single cell picking, colony forming (cloning ring and colony scrapping) and 
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serial dilution technique (McFarland, 2000; Saling-carnboriboon et al. 2003; 
Boecker et al. 2008). As well as robotic cell transfer system or manually by laser 
catapultation/PALM. In this project manual single cell picking, colony forming by 
cloning ring and serial dilution technique was performed and the single cells obtained 
successfully attached. However, after several doublings no colony propagated 
further despite hTERT-expression. Thus, it was not possible to obtain a single cell 
line (Table 8). 
Interestingly, McFarland et al. 2000 have reported that especially cell types that 
grow well at high density or in mass culture may have difficulties proliferating under 
the same culture conditions when cultured at low density or even as single cells. 
Taking this into account, culture conditions were optimized in the attempt to 
establish a single tenocyte-derived cell line. First, the percentage of fetal bovine 
serum was increased to 20 % in order to supply the single cells with more nutrients. 
Second, the culture dish was precoated with 4 μg/cm2 collagen I to enhance cell 
attachement to the matrix and proliferation. The third approach included cell culture 
dish inserts (Figure 18). The inserts were seeded with a heterogeneous population 
of hTERT-transduced tenocytes estimating that tenocytes might be stimulating 
growth of neighbouring single cells by secreting various cell factors. Despite the 
above mentioned optimizations of the culture conditions, tenocyte cloning was not 
enhanced and a single cell-derived cell line was not obtained. McFarland et al. 2000 
encountered the same problems with bovine, ovine, hamster and turkey myogenic 
satellite cells. Using chick and hamster satellite cells, the authors discovered that the 
cells begin to differentiate and fuse at low cell densities, which hinders their 
proliferation. Interestingly, the clonal propagation of chick and hamster satellite cells 
was successfully stimulated by adding 10-20 ng/ml fibroblast growth factor. Based 
on this, we suggest that single tenocytes in vitro may also be lacking a certain 
growth factor that stimulates their proliferation and therefore are not able to 
expand and form a cell clone.
Another factor that may play a role results from the findings of Schulze-Tanzil et al. 
2004. The group showed that human tenocytes in monolayer under normal culture 
conditions exhibit long cytoplasmic processes with direct contact with neighbouring 
cells. Furthermore, the authors observed that the expression of tenocyte specific 
markers such as collagen I and Scleraxis increased during culture and prior to 
production of ECM, the tenocytes made an intimate contact. Taken together these 
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results indicate that possible reasons for non-proliferating single tenocytes could be 
the lack of growth or other cell factors, and cell-cell contact.
Extension of lifespan and prevention of replicative senescence
In the next part of the project, the growth behaviour and the entry into senescence 
of untransduced and transduced tenocytes was monitored. 
HTERT-transduced tenocytes were cultured twice as long as untransduced 
tenocytes (Figure 19 and Figure 20). Moreover, HTD2 hTERT and HTD5 hTERT cells 
kept their typical, spindle-shaped morphology even in late passages (Figure 21). 
Finally, in comparison to untransduced tenocytes, the hTERT-expressing cells 
showed a background level or low β-galactosidase activity (Figure 23). 
At first, upon viral treatment and hTERT transduction of tenocytes we detected 
reduced population doubling compared to untransduced cells. This is in contrast to 
most of the studies where hTERT expression in hMSCs, fibroblasts, human 
mammary epithelial cells and lens epithelial cells led to increased cellular proliferation 
(Boecker et al. 2008; Gorbunova et al. 2003; Smith et al. 2003; Xiang et al. 2002). 
However, some groups reported similar to our findings. For example 
Techangamsuwan et al. 2009 transfected adult canine Schwann cells and olfactory 
ensheathing cells with hTERT. These cells also showed a decreased proliferation rate. 
Furthermore Klinger et al. 2006 reported a significant lengthening of the population 
doubling time of hTERT-transduced vascular smooth muscle cells compared with 
control cells. At the same time, in both publications the hTERT-modified cell types 
continued to divide markedly longer than control cells. These results go in line with 
the growth kinetics of the tenocyte cell lines obtained in our study. 
In Figure 28 our results are compared to the findings of Techangamsuwan et al. 
2009 and Boecker et al. 2008. Interestingly, in most of the studies in which hTERT 
enhanced cell proliferation, the transgene was introduced at a time when telomere 
length had already reached a critical point. In the present study ectopic hTERT was 
introduced in early passages, a time point when the primary cells have lost their 
endogenous hTERT expression. We have not examined the telomere length of the 
cells at the time of infection and hTERT-transduction. Thus, we could suggest that 
the time frame for cell treatment (infection, hTERT-transduction) might be an 
important factor and could explain the differences in the cell behaviour.
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Another factor could be the age of the donor. The introduction of hTERT can rescue 
the cells from replicative senescence but can not reverse the biochemical aging of 
the cells such as chromosomal instabilities, methylation events and mitochondrial 
damages (Klinger et al. 2006). In our study, the tenocytes derived from donors that 
were around 60 years of age. Tenocytes immortalized by hTERT from far younger 
donors would supposedly show a higher proliferation rate, presuming that ectopic 
hTERT expression would lead to the same proliferation rate as seen in untransduced 
tenocytes.
Finally, a crucial factor could be the viral treatment itself. Some cell types might be 
more sensitive to the chemicals than others. A mock-transfected tenocyte cell line 
could have been good to compare with. Mock-transfected cells are cells that are 
Figure 28. (A and B) growth curves of the present study. HTD2 hTERT and HTD5 hTERT had lower 
population doubling compared to the untransduced primary cells. Similar finding is demonstrated in 
(C) - olfactory ensheathing cells also showed reduced proliferation after introduction of hTERT 
which was independent of FGF-2 treatment (Techangamsuwan et al. 2009). An opposing finding is 
shown in (D) hTERT-transduced hMSCs and single cell picked clones (SCP-1,9,11,12) exhibited 
higher population doubling level compared to untransduced hMSCs (Boecker et al. 2008).  
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transfected with the plasmid alone, therefore the effect of the gene of interest 
alone could be revealed as well as the impact of the lentiviral transfection on the 
growth kinetics of the tenocytes.
Taken together, all these factors might lead to a noteably decreased proliferation 
rate in virally treated and hTERT-transduced cells. Still, hTERT-transduced tenocytes 
divided far beyond the entry into senescence of the control tenocytes, despite the 
lower proliferation rate. Furthermore, a senescence associated 
β-galactosidase assay was performed. In agreement with the results of other 
studies (Boecker et al. 2008, Wang et al. 2005), we found that hTERT-transduced 
tenocytes show very low β-galactosidase activity in comparison to untransduced 
control cells even at later passages. In conclusion, the hTERT-transduced tenocytes 
overcame senescence and showed a prolonged lifespan compared to primary 
tenocytes.
Immortalized tenocytes retain their tenogenic profile over time
Until recently it was not possible to distinguish tenocytes from other cell types due 
to the lack of tendon-specific gene markers. Just now that repair mechanisms of 
tendon and tendinogenesis are beginning to be understood, certain genes involved 
with tendon development and repair are brought to light (Docheva et al. 2005, 
Shukunami et al. 2006, James et al. 2008). Thus for this project a tenogenic profile 
was selected, consisting of a set of tendon related genes like collagen I and III, 
matrix proteins (Decorin, COMP, Tenascin C) and transcription factors (EphA4, Six1, 
Eya1). In this study we analysed these genes on RNA level by RT-PCR. Based on this 
analysis, first, tenocytes can be distinguished from other cell types and second the 
expression changes of the individual genes can be monitored over time. Moreover 
the tenocyte cell lines express tendon related genes such as scleraxis, collagen I and 
III, COMP and EphA4 that are partly also expressed in developing tendon during 
embryogenesis.
Our results demonstrate that the isolated cells were indeed tenogenic and 
furthermore that neither the control tenocytes nor the hTERT-transduced 
tenocytes lost their expression profile over time. These findings differ from 
previously recorded data by Yao et al. 2006. The authors evaluated the expression 
of collagen I, collagen III and Decorin on protein level and observed that their 
expression decreased in higher passage number. Thus they concluded that the 
phenotype of tenocytes rapidly drifts with progressive passage of the culture. 
Similar to this project, Salingcarnboriboon et al. 2003 monitored SV40 immortalized 
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mouse tenocytes during prolonged culture. Although they did not examine the 
variation of the expression of the genes over time, the expressed genes encoding 
scleraxis, six1, COMP, EphA4 and collagen I made it apparent that these cell lines 
kept their tendon cell property on RNA level despite immortalization comparable to 
the results in this project. 
Another well-known tendon-specific marker gene is Tenomodulin. It is involved in 
tenocyte proliferation and tendon maturation and is used as a marker for tenocytes 
in culture. In the study presented here, no TNMD expression was detectable neither 
in hTERT-transduced tenocytes nor in untransduced tenocytes when analysed by 
RT-PCR after passage 1. Our observations go in line with the data of Shukunami et 
al. 2006. Using both trypsin and collagenase digestion methods they isolated 
tenocytes from leg tendons at stage 41 chick embryos and analysed TNMD 
expression by northern blot. The authors concluded that tenomodulin transcripts are 
lower in avian tenocytes having been cultured over prolonged periods of time than 
they are in native tendons. 
We therefore assumed that a long-term cultivation of tenocytes in high density, 
particularly with the formation of three-dimensional structures, mimics the united 
cell structure of the in vivo situation. This was supported by the proven restored 
expression of TNMD in tenocytes after 90 days in high density culture. 
Taken together in our model system hTERT-transduced tenocytes maintained the 
expression of the selected tendon-specific genes during prolonged periods of in 
vitro cultivation. This suggests that HTD2 hTERT and HTD5 hTERT cells are no 
subject of phenotypic drift and dedifferentiation.
Tenocytes transduced by lentivirus and hTERT possess no tumourigenicity in vitro
Some genetic and epigenetic changes can lead to neoplastic transformation, thus 
enabling a cell population to proliferate independently of both external and internal 
signals that normally restrain growth. Cell populations that are transformed in this 
way for instance show reduced requirements for extracellular growth factors and are 
not restricted by cell-cell contact. Anchorage-independent growth and with it the 
soft agar assay which is used to assess the cells’ tendency to transfer malignantly is 
one of the most important indications for tumourigenic transformation of cells (in 
vitro). As discussed above hTERT gene transfer may lead to neoplastic 
transformation of the cells. Even though lentiviral gene transfer makes the cells less 
prone to malignant transformation than retroviral gene transfer hTERT-transduced 
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tenocytes were tested for anchorage-independent growth by soft agar assay to rule 
out growth-deregulation. HTERT-transduced tenocytes in contrast to HT1080 
(positive control) did not form colonies in soft agar. Our results are similar to the 
data of Boecker et al. 2008, who reported that hTERT-transduced hMSCs showed 
contact inhibition, while the control tumour cell line expanded into colonies. 
Furthermore, the group tested whether hTERT-transformed hMSCs show tumour 
formation in vivo by injecting the cells subcutaneously into nude mice. None of the 
tested clones formed a tumour at the injection site, whereas an extensive tumour 
growth was observed in HT1080 injected mice as a positive control. Hence, the 
next step in our project could be a similar in vivo analysis of hTERT-transduced 
tenocytes. In conclusion the generated tenocyte cell lines HTD2 hTERT and HTD5 
hTERT did not demonstrate anchorage-independent growth in vitro suggesting no 
malignant transformation. 
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6. CONCLUSIONS
The goal of the project was to establish and characterize immortalized human 
tenocyte cell lines by overexpression of the human telomerase reverse transcriptase 
gene. Based on our results, the following can be concluded:
1. Primary human tenocytes were successfully obtained and cultured in vitro.
2. Using lentiviral approach, hTERT cDNA was transduced in the primary cells and 
two cell lines – HTD2 hTERT and HTD5 hTERT were generated. 
3. HTERT transgene was successfully expressed in the cell lines as proven on RNA 
level by RT-PCR and on protein level by immunohistochemistry and quantitative 
telomerase activity test.
4. The establishment of a single-tenocyte derived cell line was not achieved. 
However, the HTD2 hTERT and HTD5 hTERT cell lines were homogeneous and 
demonstrated stable morphological appearance during prolonged culture period.
5. HTERT-transduced tenocytes proliferated twice as long and show extended 
lifespan in contrast to the control cells and no significant β-galactosidase activity 
was detected in hTERT-transduced tenocytes.
6. HTERT-transduced tenocytes retained their tenogenic profile over time which 
was evaluated by RT-PCR analysis of selected tendon-specific gene markers.
7. Tenocytes transduced by hTERT had anchorage-dependent growth in vitro 
suggesting no malignant transformation of the generated cell lines.
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7. PERSPECTIVE
One of the main goals of tissue engineering is to create viable tissue equivalents in 
vitro. This can only be achieved by obtaining live and metabolically active cells that 
are able to repair a defect site through their continuous matrix synthesis. Until now, 
many questions concerning cell-based strategies for tissue engineering of tendon 
remain unanswered. Apart from the choice of the most suitable cell type and 
treatment protocol, several further aspects have to be considered, such as adequate 
carrier materials for the delivery of the cells, supportive treatment measures to 
additionally enhance tendon regeneration (e. g. the application of proteins that can 
promote tendon healing), and various optimizations to ensure cell survival upon 
transplantation.  
In comparison to other connective tissues tendon cell research has been primarily 
hampered by the lack of appropriate human cell lines allowing the long-term 
molecular characterization of the tenocytes in vitro. Moreover, prior to clinical 
applications in most cases animal models need to be developed to ensure the safety 
and effectiveness of the tissue engineering application. Therefore standardized cell 
populations and in vivo animal models are indispensible for the development of 
appropriate tissue engineering strategies for tendon repair and reconstruction. 
Furthermore such in vitro and in vivo models can be very valuable for testing of 
novel tendon substitutes suitable for clinical applications or to assess new innovative 
regenerative strategies. 
Thus, the human tenocyte cell lines established in this project will be suitable for 
extended molecular characterization in vitro and will help to better understand the 
tenocyte lineage. At the moment the project is repeated with far younger tenocyte 
donors to eliminate the reservations of the cell line of this project due to the 
reduced proliferation capacity. The immediate object is the application of the cell line 
in a mouse model. 
67
8. SUMMARY
Development of the musculosceletal system requires coordinated formation of 
distinct types of tissues, including bone, cartilage, muscle and tendon. Compared to 
muscle, cartilage and bone, molecular, cellular and developmental biology of tendon 
have not been well understood due to the lack of tendon cell lines. In addition tissue 
engineering of tendon is hampered by the rather difficult retrieval of tenocytes and 
their senescence-associated growth arrest during culture. Therefore the purpose of 
this study was to establish and characterize human tendon cell lines. 
Two tendon cell lines (HTD2 hTERT and HTD5 hTERT) were established using 
lentiviral gene transfer to ectopically express hTERT. The cell lines stably expressed 
hTERT on RNA and protein level. Untransduced cultured tenocytes show only a 
background level of telomerase activity, but it was significantly increased by hTERT 
transduction. Ectopic expression of hTERT led to an extended lifespan and prevented 
senescence while the cells kept their typical spindle-shaped morphology of young 
primary human tenocytes. Moreover, in comparison to untransduced tenocytes the 
cells possessed significantly lesser β-galactosidase activity indicating that they had 
not entered a senescent state. Throughout the entire culturing period the hTERT-
transduced tenocytes expressed tendon-related genes such as those encoding 
collagen I, collagen III, Tenascin C, EphA4, Eya1, scleraxis, Six and COMP. Using soft 
agar assay, no malignant transformation was shown by the hTERT expressing 
tenocytes. In conclusion, extending the lifespan of human tenocytes by ectopic 
expression of hTERT using lentiviral gene transfer may be an attractive and safe way 
to generate cells allowing extensive molecular characterization and development of 
novel tissue engineering applications.
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9. ZUSAMMENFASSUNG
Die Entwicklung des muskuloskeletalen Systems erfordert die koordinierte 
Entwicklung von verschiedenen Gewebearten wie Knochen, Knorpel, Muskel und 
Sehne. Im Gegensatz zu Knochen, Knorpel und Muskel weiß man bisher nicht viel 
ueber die Molekular-, Zell- und Entwicklungsbiologie von Sehnen. Der Grund dafuer 
sind fehlende Tenozytenzelllinien. Außerdem wird das Tissue Engineering von Sehnen 
durch die schwierige Gewinnung von Sehnenzellen und dem seneszenzbedingten 
Wachstumsstillstand unter Kulturbedingungen behindert. Daher war es Ziel dieses 
Projektes eine humane Tenozytenzelllinie zu etablieren und zu charakterisieren. 
Mittels lentiviralem Gentransfer wurden zwei Tenozytenzelllinien (HTD2 hTERT und 
HTD5 hTERT) hergestellt welche ektop hTERT exprimieren. Beide Zelllinien 
exprimieren stabil hTERT sowohl auf RNA- als auch auf Protein-Ebene. Im Hinblick 
auf Telomerase-Aktivitaet zeigen untransduzierte Sehnenzellen in Kultur lediglich 
einen Hintergrundwert, waehrend die hTERT-Transduktion die Aktivitaet signifikant 
erhoeht. Ektope Expression von hTERT fuehrte zu einer verlaengerten Lebensdauer 
und verhinderte die Seneszenz der Zellen. Gleichzeitig behielten die Tenozyten ihre 
typische spindelfoermige Morphologie. ueberdies zeigten die Zellen im Vergleich zu 
untransduzierten Tenozyten signifikant weniger β-Galactosidase-Aktivitaet und dies 
weißt darauf hin, dass die Zellen noch nicht in den Zustand der Seneszenz 
uebergegangen sind. Waehrend der gesamten Kulturperiode exprimierten die 
hTERT-transduzierten Tenozyten sehnenspezifische Gene wie Kollagen I, Kollagen III, 
Tenascin C, EphA4, Eya1, Scleraxis, Six1 und COMP. Unter Verwendung eines Soft-
Agar-Assays konnte gezeigt werden, dass die hTERT exprimierenden Tenozyten 
keiner boesartigen Transformation unterlagen. 
Zusammenfassend kann gesagt werden, dass die Verlaengerung der Lebensdauer 
von humanen Tenozyten durch ektope Expression von hTERT mittels lentiviralem 
Gentransfer eine attraktive und sichere Moeglichkeit ist, um Zellen herzustellen die 
eine ausfuehrliche molekulare Charakterisierung und die Entwicklung von neuartigen 
Tissue Engineering Anwendungen ermoeglichen.
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11. APPENDIX
List of Abbreviations 
ADAM    A distegrin and metalloproteinases
ADAMTS    A distegrin and metalloproteinases with trombospondin motifs
bFGF     basic fibroblast growth factor
BSA     bovine serum albumin
cDNA  complementary deoxyribonucleic acid
COMP    cartilage oligomeric matrix protein
DAPI     4’,6’-Diamidino-2-phenylindole
DMSO    Dimethylsulfoxide
DNA     deoxyribonucleic acid
dNTP     deoxyribonucleotide triphosphate
ECM     extracellular matrix
EDTA     ethylenediaminetetraacetic acid
e.g.      exempli gratia (for example)
EGF     epidermal growth factor
EGR-1    early growth response 1
ELISA    Enzyme Linked Immunosorbent Assay
EphA4    ephrin receptor A4
FBS     fetal bovine serum
GAPDH    glyceraldehyde-3-phosphate dehydrogenase
HGF     hepatocyte growth factor
hMSC    human mesenchymal stem cells
hTERT    human telomerase reverse transcriptase
HU     hydroxyurea
MMP    matrix metalloproteinase
NO     nitric oxide
PBS     phosphate buffered saline
PCR     polymerase chain reaction
PDGF-B    platelet derived growth factor B 
PDL     population doubling level
PDT     population doubling time
rpm     revolutions per minute
SF     scatter factor
SCP-1    single cell picked clone 1 of immortalzed hMSCs
TAE     Tris-Acetate-EDTA
TGF     transforming growth factor
VEGF    vascular endothelial growth factor
   
